Nonclinical precedent Request an invite

Which risks did regulators probe for approved small molecules?

From the FDA and EMA reviews of all 211 approved small molecules. Each answer links to the regulator's own sentence.

Check my plan against these
Short answer
What reviewers probed for each of the 211 approved small molecules.

Precedent by precedent

211 approved small molecules, with the reviewers' own words.

Adquey

difamilast · PDE4 (topical)
Immune & cytokine safety
No skin sensitisation potential in guinea pigs
“OPA-15406 ointments did not show skin sensitization potential in guinea pigs under the study conditions.”
✓ VerifiedFDA multi-discipline review, p. 61Source ↗
Biodistribution & persistence
Crosses the placenta in rats (fetal tissue levels above maternal blood)
“Tissue concentrations of radioactivity in the fetus and in fetal blood, liver, kidney, and lung were higher than maternal blood, indicating 14C-OPA-15406-dependent radioactivity crosses the placental barrier.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗

Agamree

vamorolone · Glucocorticoid receptor (dissociative)
Immune & cytokine safety
Glucocorticoid immunosuppression: TDAR inhibited in female mice and abolished in male mice at 100 mg/kg/day
“As expected from the immunosuppressive activity of vamorolone and other glucocorticoids, 100 mg/kg/day vamorolone and prednisolone doses ≥10 mg/kg/day comparably inhibited the TDAR in female mice, while TDAR was completely abolished in male animals.”
✓ VerifiedEMA assessment report, p. 28Source ↗
Biodistribution & persistence
Wide distribution (QWBA), highest in GI tract and liver; slight distribution to retinal melanin
“A subsequent Quantitative Whole Body Autoradiography (QWBA) study revealed wide tissue distribution of 14C-labelled vamorolone in pigmented rats with highest radioactivity levels in the gastrointestinal tract and liver. A slight distribution to melanin-containing pigmented layer of the retina was also detected.”
✓ VerifiedEMA assessment report, p. 22Source ↗

Alyftrek

vanzacaftor, tezacaftor and deutivacaftor · CFTR
Immune & cytokine safety
26-week rat: decreased lymphocytes in spleen, thymus and lymph nodes
“decreases in lymphocytes in the spleen, thymus, and lymph nodes for males ≥25 mg/kg/day and females ≥12.5 mg/kg/day.”
✓ VerifiedFDA integrated review, p. 150Source ↗
Biodistribution & persistence
Highest in GI tract, liver and kidneys in rats; no substantial melanin binding
“Distribution was highest in the GI-tract, liver and kidneys for all three compounds in rats. No substantial binding to melanin-containing tissues was observed.”
✓ VerifiedEMA assessment report, p. 60Source ↗

Anzupgo

delgocitinib · Pan-JAK (topical)
Immune & cytokine safety
Immunotoxic in a 4-week oral rat study, an expected immunosuppressive effect
“Delgocitinib was immunotoxic in a 4-week oral dose study in rats; however, this is an expected effect because of the pharmacological/immunosuppressive nature of delgocitinib.”
✓ VerifiedFDA integrated review, p. 79Source ↗
Biodistribution & persistence
Binding to melanin-containing tissues (skin, eyes) in dogs
“Distribution study in dogs with 14C-delgocitinib indicated binding of radioactivity to melanin-containing tissues including skin and eyeballs.”
✓ VerifiedEMA assessment report, p. 25Source ↗

Artesunate

artesunate · Plasmodium (antimalarial)
Immune & cytokine safety
Increased leukocytes and fibrinogen, indicating an inflammatory response
“In addition to reductions in red blood cells and hemoglobin, animals also had increased leukocytes and fibrinogen, indicating an inflammatory response.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Biodistribution & persistence
Highest tissue levels at 0.5 h in small intestine, spleen and bone marrow; CNS levels low but persistent
“Highest tissue concentrations were observed 0.5 hr after dosing, in the small intestine, spleen and bone marrow. CNS concentrations were low but persisted until the end of the study, similar to other tissues.”
✓ VerifiedEMA assessment report, p. 22Source ↗

Augtyro

repotrectinib · ROS1/TRK
Immune & cytokine safety
Non-adverse decreased lymphocytes in blood and lymphoid organs in rats and monkeys
“In rats, non-adverse decreased lymphocytes in circulation and in multiple lymphoid organs were observed at ≥15 mg/kg (M) and at ≥5 mg/kg (F).”
✓ VerifiedEMA assessment report, p. 31Source ↗
Biodistribution & persistence
Wide distribution, highest in pigmented skin, uveal tract, liver and kidney; low CNS penetration
“The distribution of repotrectinib was widespread by 1 hour post-dose with the highest exposures in pigmented skin, uveal tract, liver, renal cortex, and kidneys with low distribution into non-circumventricular CNS tissue (protected by blood-brain barrier).”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗

Avmapki Fakzynja Co-pack

avutometinib and defactinib · RAF/MEK clamp; FAK
Immune & cytokine safety
Avutometinib: lymph node follicular hyperplasia, plasma cells and inflammatory infiltrates in rats and monkeys
“Histopathology findings of hyperplasia of the lymph follicle, increased plasma cells of the medulla, and inflammatory cell infiltrates in the sinus of the lymph nodes were noted in both species.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Biodistribution & persistence
Defactinib: distributes to pigmented skin and uveal tract, suggesting melanin affinity
“radioactivity was reported in the pigmented tissues (pigmented skin, eye [uveal tract, lens]), indicating a possible affinity of defactinib to melanin.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗

Ayvakit

avapritinib · KIT/PDGFRA
Immune & cytokine safety
Lymphoid system effects (spleen, thymus) did not reverse
“All effects were reversible or reversing with three notable exceptions: effects in the lymphoid system (spleen and thymus), brain and the gonads.”
✓ VerifiedEMA assessment report, p. 50Source ↗
Biodistribution & persistence
Pigmented rats: uveal tract and skin levels 2-330-fold higher than in albino rats, with slower elimination
“The concentration of [14C]-avapritinib-derived radioactivity in the uveal tract and skin of pigmented Long Evans rats was eliminated more slowly and was approximately 2 to 330-fold higher than in these tissues in nonpigmented rats.”
✓ VerifiedEMA assessment report, p. 34Source ↗

Balversa

erdafitinib · FGFR1-4
Immune & cytokine safety
Skin sensitiser in the murine local lymph node assay
“Erdafitinib was considered to cause skin sensitization in the murine local lymph node assay”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Biodistribution & persistence
Prolonged retention in eye (t1/2 182.5 h) and lacrimal gland (t1/2 135.7 h)
“By 24/72 hours post dose, radioactivity was either close to or below the limit of quantification in the majority of the tissues, except the eye (T1/2 182.5 hours) and lacrimal gland (T1/2 135.7 hours).”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗

Barhemsys

amisulpride · Dopamine D2/D3 receptor
Immune & cytokine safety
High-dose males: 24% decrease in lymphocytes and 19% decrease in total white blood cells
“HD males: 24% decrease in lymphocytes and 19% decrease in total white blood cells”
✓ VerifiedFDA multi-discipline review, p. 67Source ↗
Biodistribution & persistence
Radioactivity retained in meninges up to 336 h and uveal tract up to 840 h, suggesting melanin affinity
“The levels of radioactivity detected in the meninges up to 336 hours and uveal tract up to 840 hours post-dose suggest an affinity of amisulpride for the melanin pigmented tissues.”
✓ VerifiedFDA multi-discipline review, p. 63Source ↗

Baxfendy

baxdrostat · Aldosterone synthase (CYP11B2)
Immune & cytokine safety
Decreased lymphocytes in spleen, thymus and mesenteric lymph nodes in 39-week monkey study (non-adverse)
“Baxdrostat was well tolerated despite dehydration (increased incidence of thinness and skin tenting), reduced body weight gain, and histological changes in adrenals, kidneys, spleen, thymus, and mesenteric lymph nodes (decreased lymphocytes).”
✓ VerifiedFDA pharmacology/toxicology review, p. 19Source ↗
Biodistribution & persistence
Wide distribution, highest in adrenal, liver, cecum and kidney; low brain/spinal cord; melanin binding
“Tissue distribution studies revealed widespread tissue distribution with highest exposures in adrenal gland, liver, cecum, and kidney (tissue-to-plasma ratios up to 17.3 for adrenal gland). Brain and spinal cord showed substantially lower concentrations, while pigmented tissues demonstrated selective melanin binding in Long Evans rats.”
✓ VerifiedFDA pharmacology/toxicology review, p. 17Source ↗

Beqalzi

sonrotoclax · BCL-2
Immune & cytokine safety
Lymphoid depletion; one mouse death from opportunistic infection secondary to lymphoid depletion
“Mortality was only noted in 1 male at 100 mg/kg/day and was most likely caused by an opportunistic infection secondary to lymphoid depletion.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗
Biodistribution & persistence
Mouse distribution to intestine, kidney, spleen, liver, muscle, bone marrow and uterus
“Sonrotoclax distribution in the mouse included the small intestine, large intestine, kidney, spleen, liver, muscle, bone marrow, and uterus.”
✓ VerifiedFDA multi-discipline review, p. 26Source ↗

Blujepa

gepotidacin · Bacterial topoisomerases (gyrase/topo IV)
Immune & cytokine safety
Thymic lymphoid depletion in high-dose rats, considered stress-related
“Minimal to mild lymphoid depletion of the thymus in high dose rats appears likely to be stress-related (5/10 males, 2/10 females).”
✓ VerifiedFDA integrated review, p. 122Source ↗
Biodistribution & persistence
Rat QWBA: prolonged retention in ocular uveal tract and meninges up to 35 days
“At 7 days only the ocular uveal tract was above 10 μg equiv/g (at 125.551 μg equiv/g), and at 35 days the meninges (3.318 μg equiv/g) and ocular uveal tract (84.123 μg equiv/g) were the only tissues above the LoQ.”
✓ VerifiedFDA integrated review, p. 116Source ↗

Brexafemme

ibrexafungerp · Fungal glucan synthase
Immune & cytokine safety
Thymic lymphoid necrosis in high-dose rats (1-month study)
“Thymus: Very slight lymphoid necrosis in the thymus was observed in 3/10 HD males and moderate lymphoid necrosis was observed in 1/10 HD females.”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Biodistribution & persistence
Extensive tissue distribution (large intestine, pituitary, bone marrow, liver); no radioactivity in brain/CNS
“Extensive distribution to tissues was observed with the highest concentrations in large intestine, pituitary gland, bone marrow, and liver followed by lung and kidney, minimal concentrations in male reproductive organs, and no detectable radioactivity in brain and CNS tissues.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗

Brinsupri

brensocatib · DPP1 (cathepsin C)
Immune & cytokine safety
No dedicated immunotoxicity studies; weight-of-evidence evaluation showed no concerning immunotoxic risk
“No dedicated immunotoxicity investigations were conducted and there was no evidence of a concerning immunotoxicological risk based on a comprehensive weight-of-evidence evaluation in”
✓ VerifiedEMA assessment report, p. 57Source ↗
Biodistribution & persistence
Highest levels in liver, preputial gland and uveal tract, suggesting melanin binding; low CNS penetration
“Highest radioactivity tissue concentrations were in the liver and preputial gland in albino rats and in the uveal tract in the pigmented rats, suggesting melanin binding of brensocatib or its metabolites. There is low CNS penetration.”
✓ VerifiedEMA assessment report, p. 53Source ↗

Brukinsa

zanubrutinib · BTK
Immune & cytokine safety
Lymphoid depletion in dogs (also rats); inflammatory responses with elevated WBCs
“Other findings in the dog included lymphoid depletion and reduced red blood cells (RBCs) and lineages, which may be at least partially related to bleeding noted on histopathology.”
✓ VerifiedFDA multi-discipline review, p. 27Source ↗
Biodistribution & persistence
Preferential distribution to stomach, small intestine and liver; very low brain and testis levels
“BGB-3111 showed preference for stomach, small intestine and liver. Very low concentration was found in brain and testes, however elimination from testes appeared to be slower than for other tissues.”
✓ VerifiedEMA assessment report, p. 33Source ↗

Byfavo

remimazolam · GABA-A receptor (benzodiazepine site)
Immune & cytokine safety
No immune system findings
“There were no findings indicating an influence of remimazolam on the immune system.”
✓ VerifiedEMA assessment report, p. 27Source ↗
Biodistribution & persistence
Very limited placental transfer; readily enters breast milk
“Placenta penetration of remimazolam and/or its derivatives was very limited and did not lead to a sustained exposure of the fetus. Remimazolam and/or its derivatives easily accessed breast milk; the concentrations determined in milk were linked to maternal plasma concentrations.”
✓ VerifiedEMA assessment report, p. 20Source ↗

Bylvay

odevixibat · IBAT
Immune & cytokine safety
No effects on thymus, spleen, lymph nodes or bone marrow; dedicated immunotoxicity studies not performed
“The risk of immunotoxicity has been evaluated based on results from the standard toxicity studies. No obvious signs in related organs have been detected in response to odevixibat treatment (e.g. changes in thymus, spleen, lymph nodes, bone marrow).”
✓ VerifiedEMA assessment report, p. 54Source ↗
Biodistribution & persistence
Poorly absorbed; radioactivity mainly in GI tract contents, none detected in CNS
“Most of the radioactivity was found in the content of the gastrointestinal tract, whereas none was detected in the central nervous system (CNS).”
✓ VerifiedFDA integrated review, p. 77Source ↗

Cabenuva

cabotegravir and rilpivirine · HIV-1 integrase; NNRTI
Immune & cytokine safety
Negative rat TDAR; no skin sensitization
“CAB was negative for immunosuppression in a T-cell–dependent antibody response (TDAR) study in rats, and was not associated with skin sensitization, skin irritation, ocular irritation, or phototoxicity.”
✓ VerifiedFDA integrated review, p. 128Source ↗
Biodistribution & persistence
Low brain penetration; detected in rat fetal tissue
“Very small amounts were also detected in the brain, indicating that low levels of CAB cross the blood–brain barrier. CAB was also detected in fetal tissue in an investigative toxicokinetic (TK) study in pregnant rats.”
✓ VerifiedFDA integrated review, p. 126Source ↗

Camzyos

mavacamten · Cardiac myosin
Immune & cytokine safety
Thymus decreased in size from decreased cellularity in rats and dogs
“Other target organs of toxicity in both rats and dogs were liver (centrilobular necrosis, congestion and vacuolation), lungs (increased alveolar macrophages and inflammation) and thymus (decrease in size as a result of decreased cellularity).”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Biodistribution & persistence
Low CNS levels; selective association with melanin-containing eye tissues in rat QWBA
“Low radioactivity concentrations were documented in central nervous system tissues (cerebellum, cerebrum, medulla, and spinal cord). Low levels of [14C]MYK-461-derived radioactivity were selectively associated with melanin-containing tissues of the eye”
✓ VerifiedFDA pharmacology/toxicology review, p. 101Source ↗

Cibinqo

abrocitinib · JAK1
Immune & cytokine safety
Monkey KLH assay: dose-related reduction in IgG and IgM from 15 mg/kg/day, with partial recovery
“A KLH study was performed in monkeys from the 9-month study. Abrocitinib exposure gave reduced IgG and IgM values (with dose relation) from 15mg/kg/day with partial recovery.”
✓ VerifiedEMA assessment report, p. 35Source ↗
Biodistribution & persistence
Low CNS penetration (brain:plasma AUC ratio <0.1)
“The brain:plasma AUClast ratio was <0.1, indicating that the passage over blood-brain barrier was low.”
✓ VerifiedEMA assessment report, p. 30Source ↗

Cobenfy

xanomeline and trospium · Muscarinic M1/M4 agonist; peripheral antagonist
Immune & cytokine safety
Moderate skin sensitizer in mouse LLNA (EC3 125 µg/cm2)
“Xanomeline is a moderate skin sensitizer with an EC3 (3-fold stimulation index) potency of 125 µg/cm2”
✓ VerifiedFDA integrated review, p. 199Source ↗
Biodistribution & persistence
Low xanomeline exposure in rat fetal tissues (potential placental transfer); xanomeline and trospium in pup blood (potential milk transfer)
“Subcutaneous administration of xanomeline to pregnant rats resulted in low levels of exposure to xanomeline and its metabolites in fetal tissues, suggesting potential transplacental transfer of xanomeline and/or its metabolites. In pre- and postnatal developmental studies in the rat, after maternal oral administration, xanomeline and trospium were detected in neonatal pup blood on postnatal Day 4, suggesting potential lactational transfer of both drugs.”
✓ VerifiedFDA integrated review, p. 163Source ↗

Cosela

trilaciclib · CDK4/6
Immune & cytokine safety
Failure to clear catheter-related bacterial infections, suggesting compromised immune response from leukocyte suppression
“The bacterial infections likely originated from indwelling catheters but the failure to clear the infections suggest a compromised immune response, consistent with trilaciclib-mediated leukocyte and thrombocyte suppression during treatment.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Biodistribution & persistence
Highest in thyroid, kidney, harderian, adrenal and lacrimal glands, spleen and liver; eye uveal tract and meninges in pigmented rats
“Highest radioactivity, representing drug or metabolite tissue distribution, was seen in thyroid, kidney, harderian gland, adrenal gland, lacrimal glands, spleen, and liver in non-pigmented rats with additional distribution in eye/eye uveal tract and meninges in pigmented rats.”
✓ VerifiedFDA pharmacology/toxicology review, p. 35Source ↗

Crenessity

crinecerfont · CRF1 receptor
Immune & cytokine safety
Rat TDAR study: small changes in leukocytes, lymphocyte subsets and T-cell-dependent antibody response (males); no remarkable immunotoxicity
“The changes in leukocytic parameters and lymphocyte subpopulation and T-cell-dependent antibody responses were small in magnitude and occurred in one sex (males) and showed no remarkable evidence of immunotoxicity in rats.”
✓ VerifiedFDA integrated review, p. 222Source ↗
Biodistribution & persistence
Crosses placenta to fetal liver at low levels; low exposure in brain, skin and testis
“Crinecerfont crossed the placenta and distributed to the fetal liver (at low levels) in pregnant rats and rabbits. Low crinecerfont exposure was observed in brain, skin, and testis.”
✓ VerifiedFDA integrated review, p. 183Source ↗

Dayvigo

lemborexant · Orexin OX1/OX2 receptors
Immune & cytokine safety
No drug-related findings in immune function assessments (immunophenotyping, NK activity, granulocyte function, cytokine release)
“There were no significant drug-related findings in any immune function assessments: Immunophenotyping, natural killer cell activity, peripheral blood granulocytes functions, cytokine release.”
✓ VerifiedFDA multi-discipline review, p. 64Source ↗
Biodistribution & persistence
Rapid wide distribution, highest in liver; no melanin accumulation; crosses BBB with CSF above plasma
“Lemborexant is rapidly and extensively distributed to tissues in rats and monkeys with the highest levels found in liver and no accumulation in melanin-containing tissues in rats. Lemborexant and its metabolites readily cross the blood brain barrier and drug concentrations in cerebral spinal fluid are higher than that of plasma.”
✓ VerifiedFDA multi-discipline review, p. 47Source ↗

Defencath

taurolidine and heparin · Antimicrobial catheter lock
Immune & cytokine safety
Not irritating intradermally and nonsensitizing in guinea pigs
“Guinea pig studies with Defencath showed that the product was not irritating when injected intradermally and it was nonsensitizing in these animals.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Biodistribution & persistence
Not studied; ADME/PK studies not conducted given negligible systemic exposure
“ADME/PK studies were not conducted with Defencath because the product is not intended for systemic administration and clinical exposure to its components is negligible when used as directed.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗

Dojolvi

triheptanoin · Anaplerotic energy substrate
Immune & cytokine safety
Not a dermal sensitizer in guinea pigs
“Triheptanoin was not a dermal sensitizing agent in male albino guinea pigs.”
✓ VerifiedFDA integrated review, p. 61Source ↗
Biodistribution & persistence
Dose-related exposure to heptanoate and C5 ketone metabolites without accumulation over 9 months in minipigs
“The dose-related increase in the primary metabolites (heptanoic acid and C5 ketone bodies) showed systemic exposure to UX007, but no accumulation after 9 months of treatment.”
✓ VerifiedFDA integrated review, p. 82Source ↗

Duvyzat

givinostat · Histone deacetylase (class I/II)
Immune & cytokine safety
Lymphoid depletion with atrophy of thymus, lymph nodes, bone marrow and spleen; partially reversible
“This lymphoid depletion led to atrophies of thymus, lymph nodes, bone marrow and spleen. This interference of givinostat with the white blood cell lineage likely reflects its anti-inflammatory activity and was partially reversible in rats and monkeys.”
✓ VerifiedEMA assessment report, p. 31Source ↗
Biodistribution & persistence
Rat: mainly GI tract and elimination organs (liver, kidney, bladder); no significant brain distribution
“In rats, givinostat primarily distributed into gastrointestinal tract tissue (intestine > duodenum > stomach) and in organs involved in elimination (liver > kidney > bladder), but not significantly into the brain.”
✓ VerifiedEMA assessment report, p. 22Source ↗

Egaten

triclabendazole · Fasciola (tubulin)
Immune & cytokine safety
Guinea pig sensitization: no reaction after epidermal challenge; contact dermatitis unlikely
“No difference between the test and the control group was seen after epidermal challenge application, which suggests that the drug may not produce contact dermatitis.”
✓ VerifiedFDA multi-discipline review, p. 64Source ↗
Biodistribution & persistence
Extensive distribution in rats; slight accumulation after repeat dosing, 2-fold (thyroid, skin) to 6-fold (brain)
“Drug distribution was extensive in rats with only a slight accumulation in most organs and tissues investigated after 10 daily oral doses of 1 mg/kg. The accumulation of radioactivity was between 2-fold (thyroid and skin) and 6-fold (brain)”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗

Ekterly

sebetralstat · Plasma kallikrein
Immune & cytokine safety
Thymus microscopic findings in monkeys at 300 mg/kg/day and above
“Microscopic findings in adrenals, kidneys and thymus were also apparent at sebetralstat 500/300 or 300 mg/kg/day.”
✓ VerifiedEMA assessment report, p. 28Source ↗
Biodistribution & persistence
Limited placental transfer in rats (QWBA); moderate melanin binding
“The extent of placental transfer of total radioactivity was investigated in rats (study 187593) by QWBA where limited placental transfer was observed. Moreover, data suggest a moderate binding affinity of sebetralstat for melanin.”
✓ VerifiedEMA assessment report, p. 24Source ↗

Ensacove

ensartinib · ALK
Immune & cytokine safety
Splenic lymphoid depletion and marked bone marrow hypocellularity in the 4-week dog study
“Additional findings in the 4-week dog study included increased creatine kinase, histologic lymphoid depletion in the spleen, and up to marked hypocellularity of the bone marrow.”
✓ VerifiedFDA integrated review, p. 130Source ↗
Biodistribution & persistence
Persists in testes at 24 h; distributes to melanin-containing skin; eye not evaluated
“While ensartinib was eliminated from most tissues after 24 hours, 87% of the Cmax was still detected in the testes. Ensartinib was detected in the skin (melanin-containing tissue), but distribution to the eye was not evaluated in this study.”
✓ VerifiedFDA integrated review, p. 112Source ↗

Evrysdi

risdiplam · SMN2 splicing
Immune & cytokine safety
Decreased B lymphocytes in juvenile rats
“Decreases in the B lymphocyte relative percentages and absolute counts were observed in HD males and females at all doses.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Biodistribution & persistence
Strong melanin binding: high, persistent levels in choroid/RPE, iris and sclera in rats and monkeys
“Substantial distribution into melanin-containing parts of the eye (choroid + retinal pigment epithelium [RPE], iris, sclera) was demonstrated in rats and monkeys, and ocular RIS concentrations remained high for considerable periods after the end of dosing.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗

Exblifep

cefepime and enmetazobactam · PBPs; beta-lactamase (enmetazobactam)
Immune & cytokine safety
Guinea pig maximization test: no skin sensitization
“At 24 and 48 hours after the challenge patch removal, the guinea pigs induced and challenged with AAI101 did not exhibit any skin responses and received the same Magnusson and Kligman grades (0% positive reaction) as the vehicle control group.”
✓ VerifiedFDA integrated review, p. 112Source ↗
Biodistribution & persistence
No melanin binding; no preferential retention in skin, eye or uveal tract
“There was no preferential distribution to or retention in the skin, the eye or the uveal tract, i.e., no specific binding of [14C]-enmetazobactam and drug related radioactivity to melanin was indicated.”
✓ VerifiedEMA assessment report, p. 26Source ↗

Exkivity

mobocertinib · EGFR exon 20 insertion
Immune & cytokine safety
Increased lymphoid cellularity in lymph nodes in rats and dogs
“Additional target organs in both species included the reproductive system (atrophy and single cell necrosis), lymph nodes (increased lymphoid cellularity), digestive tract (decreased epithelial thickness), eyes (atrophy of the corneal epithelium), and larynx (decreased epithelial thickness).”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Biodistribution & persistence
Wide distribution in rats, including uveal tract; low brain penetration
“Following single oral administration, [14C]mobocertinib-derived radioactivity distributed widely to rat tissues including the liver, adrenal gland, kidney, alimentary canal, uveal tract, and thyroid but brain penetration was low.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗

Exxua

gepirone · 5-HT1A receptor
Immune & cytokine safety
Increased mesenteric lymph node plasmablasts at end of dosing (highest at 70 mg/kg), reversible after recovery
“At the end of the dosing period (Day 42) a greater number of plasmablasts were observed in the mesenteric lymph nodes of dose group animals relative to controls with the highest numbers observed in the 70 mg/kg group. Following the recovery period (Day 56) there was no difference in lymph node plasmablasts between controls and dose group animals.”
✓ VerifiedFDA multi-discipline review, p. 55Source ↗
Biodistribution & persistence
Gepirone and/or metabolites cross the placenta; fetal radioactivity similar to maternal plasma
“The amount of radiolabel (gepirone-equivalents per gm) was essentially identical in maternal plasma and total fetus, at all time-points, and very similar for maternal and fetal hearts, whereas maternal liver levels were much (5-24-fold) greater than those in fetal liver. Geprione and/or metabolites crossed the placental barrier from mother to fetus.”
✓ VerifiedFDA pharmacology/toxicology review, p. 43Source ↗

Fabhalta

iptacopan · Complement factor B
Immune & cytokine safety
Minimal TDAR effects in 39-week dog study: reduced IgM/IgG titers to KLH
“T-Dependent Antibody Response (TDAR) assay conducted with blood from dogs in 39-week toxicology study presented minimal effects on the humoral responses with reduced IgM and/or IgG titers following primary response to KLH challenge in both genders.”
✓ VerifiedFDA integrated review, p. 161Source ↗
Biodistribution & persistence
Detected in melanin-containing eye tissues up to 168 h, suggesting ocular melanin affinity
“In pigmented animals, iptacopan was detected in melanin containing eye tissues (choroid and ciliary body) up to 168 hrs which suggests affinity to ocular melanin.”
✓ VerifiedFDA integrated review, p. 171Source ↗

Fetroja

cefiderocol · Penicillin-binding proteins
Immune & cytokine safety
Splenic germinal center development in 1- and 3-month rat studies, a response to weak antigenic stimulation; no anaphylaxis
“In the 1-month and 3-month repeat-dose toxicity studies in rats, development of germinal centers in the spleen, which suggested an enhanced antibody production, was observed. This change is considered to be an immune response possibly associated with the weak antigenic stimulation by cefiderocol, however, there was no evidence of anaphylaxis in either study.”
✓ VerifiedFDA multi-discipline review, p. 142Source ↗
Biodistribution & persistence
Low, brief CNS exposure; tissue levels mostly below plasma; no preferential melanin binding
“CNS exposure was low and brief. Most tissue levels were lower than plasma levels. Binding to RBC was negligible. Preferential binding to melanin not observed.”
✓ VerifiedFDA multi-discipline review, p. 50Source ↗

Fexinidazole

fexinidazole · Trypanosoma brucei
Immune & cytokine safety
Dog: decreased thymus weights at all doses
“In dogs, alkaline phosphatase and cholesterol increased and thymus weights decreased at all doses.”
✓ VerifiedFDA multi-discipline review, p. 57Source ↗
Biodistribution & persistence
Crosses the blood-brain barrier; brain levels about 0.6x plasma in rats
“Fexinidazole penetrated the blood brain barrier with a brain Tmax of between 2 and 8 hours after dosing in rats. The level of fexinidazole in brain was approximately 0.6 times the levels in plasma.”
✓ VerifiedFDA multi-discipline review, p. 56Source ↗

Fotivda

tivozanib · VEGFR1-3
Immune & cytokine safety
Lymphoid depletion of thymus, lymph nodes and spleen
“gastric system (stomach, duodenum and pancreas), reproductive system (ovary and corpora lutea) and lymphoid organs (lymphoid depletion of thymus, lymph nodes and spleen).”
✓ VerifiedFDA multi-discipline review, p. 30Source ↗
Biodistribution & persistence
Melanin binding to choroid of eye in pigmented rats, declining over 120 hours
“In pigmented rats, melanin binding to the choroid layer of the eye was apparent and levels decreased steadily over 120 hours post-dose.”
✓ VerifiedFDA multi-discipline review, p. 163Source ↗

Fruzaqla

fruquintinib · VEGFR1-3
Immune & cytokine safety
Immune system (thymus, spleen, lymph nodes) a target organ in dog studies
“The non-GLP dog studies identified liver, kidney, GI-tract, adrenal gland, and immune system (thymus and spleen, and lymph nodes in the 39-week study) as target organs.”
✓ VerifiedEMA assessment report, p. 41Source ↗
Biodistribution & persistence
Wide distribution; highest in GI tract, bladder, uveal tract and pigmented skin (melanin)
“Following a single oral dose of radiolabeled fruquintinib, wide distribution of fruquintinib was observed with the highest radioactivity observed in the esophagus, large intestine, small intestine, stomach, bladder, uveal tract, and pigmented skin.”
✓ VerifiedFDA multi-discipline review, p. 32Source ↗

Gavreto

pralsetinib · RET
Immune & cytokine safety
No dedicated immunotoxicity studies; decreased cellularity of haematopoietic and lymphoid organs in rats and monkeys
“Although no dedicated immunotoxicity studies were conducted with pralsetinib, some of the toxicological findings reported in repeat-dose toxicity studies were related to its actions on immune system (i.e., decreased cellularity of multiple haematopoietic and lymphoid organs in rats, and bone marrow cellularity and decreased cellularity of lymphoid organs in monkeys).”
✓ VerifiedEMA assessment report, p. 41Source ↗
Biodistribution & persistence
Wide distribution (intestine, liver, adrenal, uveal tract, pigmented skin); melanin affinity; crosses blood-brain barrier in rats
“Following single oral administration, 14C-pralsetinib-derived radioactivity distributed widely to rat tissues especially the small intestine wall, liver, adrenal gland, uveal tract, and pigmented skin. Pralsetinib crossed the blood-brain barrier in rats”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗

Gomekli

mirdametinib · MEK1/2
Immune & cytokine safety
Lymphoid hyperplasia, lymphoid depletion and increased plasma cells in lymph nodes of rats and dogs
“findings correlated with histologic signs in the lymph nodes in the 3-month studies in rats and dogs, including minimal to moderate lymphoid hyperplasia, lymphoid depletion, and increases in plasma cells, as well as hypocellularity in rats.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Biodistribution & persistence
Rat QWBA: peak tissue levels within 4 h after oral dosing; no retention in melanin-containing tissues
“For all tissues, the highest measured concentrations were observed within 4 hours and 0.5 hours post dose for the oral and IV routes, no specific retention was observed in melanin-containing tissues.”
✓ VerifiedEMA assessment report, p. 39Source ↗

Grafapex

treosulfan · DNA alkylation
Immune & cytokine safety
Myeloablative and immunosuppressive in a murine allogeneic bone marrow transplant model
“Treosulfan showed in vivo myeloablative and immunosuppressive activity in a murine allogeneic bone marrow transplant model.”
✓ VerifiedFDA multi-discipline review, p. 144Source ↗
Biodistribution & persistence
Rat: highest levels in kidney, lowest in brain
“Highest concentrations of treosulfan were observed in kidneys, and lowest quantifiable levels of treosulfan and EBDM were observed in the brain tissue.”
✓ VerifiedEMA assessment report, p. 27Source ↗

Hernexeos

zongertinib · HER2 (mutant)
Immune & cytokine safety
4-week rat: slight to moderate fluctuations in blood, spleen and thymocyte populations
“Immunotoxicology: slight to moderate fluctuations in blood, spleen, and thymocyte populations”
✓ VerifiedFDA multi-discipline review, p. 69Source ↗
Biodistribution & persistence
Minimal BBB crossing (brain:plasma ≤0.01); prolonged retention in melanin-containing ocular tissues (~470 h)
“Brain-to-plasma ratios were ≤0.01, suggesting zongertinib showed minimal crossing of the blood-brain barrier in rats. Zongertinib was detected for up to ~200 hours in the total eyeball, and up to ~470 hours in the melanin-containing region of the ocular bulb of the eye”
✓ VerifiedFDA multi-discipline review, p. 47Source ↗

Hyrnuo

sevabertinib · HER2 (mutant)
Immune & cytokine safety
Thymic atrophy and mesenteric lymph node changes in monkeys
“Additional target organs in the monkey included the thymus (up to severe atrophy, severe decreased adipose tissue), and mesenteric lymph node (marked decreased adipose tissue, slight increased cellularity).”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Biodistribution & persistence
Distribution to melanin-containing eye and skin with long-term ocular retention
“There was notable distribution of sevabertinib to the melanin-containing tissues of the eye and skin with long-term retention in the eye tissue”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗

Ibsrela

tenapanor · NHE3
Immune & cytokine safety
Lymphoid depletion in spleen and thymus in high-dose rat decedents
“Histological examinations of these animals showed hemorrhage and acute inflammation of the cecum; luminal dilatation of the duodenum, jejunum, ileum, and colon; and lymphoid depletion in the spleen and thymus.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Biodistribution & persistence
Mostly confined to GI tract; at 24 h radioactivity measurable only in liver and GI tract, plus uveal tract in pigmented rats
“Excluding the uveal tract in the Long Evans rat, radioactivity concentrations in tissues of both rat strains were measurable only in the liver and GI tract at 24 hours postdose.”
✓ VerifiedFDA multi-discipline review, p. 148Source ↗

Ibtrozi

taletrectinib · ROS1
Immune & cytokine safety
Thymic atrophy and lymph node erythrophagocytosis and foamy macrophages in monkeys
“Additional findings were noted in the thymus (atrophy), lymph nodes (erythrophagocytosis, foamy macrophages), and kidneys (basophilic casts, dilation, hyperplasia, vacuolation).”
✓ VerifiedFDA multi-discipline review, p. 78Source ↗
Biodistribution & persistence
Wide distribution in rats; melanin binding in eye and skin; choroid plexus accumulation, crosses the blood-brain barrier
“Taletrectinib was distributed throughout rat tissues. There was notable distribution of taletrectinib to melanin-containing tissues of the eyeball and skin. Taletrectinib also accumulated in the choroid plexus region of the brain indicating the drug can cross the blood brain barrier.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗

Idvynso

doravirine and islatravir · NNRTI; NRTTI
Immune & cytokine safety
Dose- and duration-dependent lymphocyte decreases in two mouse strains
“The most clinically relevant finding was dose- and duration-dependent decreases in lymphocytes, which was consistently observed in two mouse strains.”
✓ VerifiedFDA multi-discipline review, p. 192Source ↗
Biodistribution & persistence
Strong melanin binding (uveal tract) in pigmented rats; crosses placenta with significant fetal exposure
“ISL also demonstrated strong affinity for melanin-containing tissues (e.g., uveal tract) in pigmented rats and readily crossed the placental barrier in pregnant rats, resulting in significant fetal exposure.”
✓ VerifiedFDA multi-discipline review, p. 206Source ↗

Inluriyo

imlunestrant · Estrogen receptor (SERD)
Immune & cytokine safety
No dedicated immunotoxicity studies; TDAR effects in rats judged non-adverse as immune responses were still mounted
“Imlunestrant affected T-cell dependent antibody responses across studies but because animals mounted anti-KLH IgM and IgG responses it was concluded that effects on seroconversion did not functionally suppress the immune response and were considered non-adverse.”
✓ VerifiedEMA assessment report, p. 39Source ↗
Biodistribution & persistence
Persistent uveal tract retention in rat whole-body distribution, declining very slowly through 672 hours
“Concentrations in uveal tract were high through to the end of the study at 672 hours and concentrations seem to be declining only very slowly.”
✓ VerifiedEMA assessment report, p. 27Source ↗

Inqovi

decitabine and cedazuridine · DNMT (decitabine); cytidine deaminase (cedazuridine)
Immune & cytokine safety
Reversible thymic lymphoid depletion attributed to cedazuridine
“and thymic lymphoid depletion (cedazuridine, reversible) and testicular effects (partially reversible) due to decitabine.”
✓ VerifiedFDA multi-discipline review, p. 61Source ↗
Biodistribution & persistence
Cedazuridine: low tissue distribution; highest in kidney, urinary bladder and GI tract
“Overall, cedazuridine did not show a strong tendency to distribute into tissues. The metabolic/excretory tissues (kidney, urinary bladder) as well as the tissues of the GI tract contained the highest distribution of [14C]-cedazuridine derived radioactivity.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗

Inrebic

fedratinib · JAK2
Immune & cytokine safety
Bone marrow hypoplasia and lymphocyte depletion (spleen, thymus, lymph nodes) in all species; immunosuppressive
“In conclusion, fedratinib-related effects on the bone marrow (hypoplasia) and lymphoid tissues (lymphocyte depletion in the spleen, thymus and lymph nodes) in all three species are likely symptoms of exaggerated pharmacology and indicate clear immunosuppressive properties of fedratinib”
✓ VerifiedEMA assessment report, p. 34Source ↗
Biodistribution & persistence
Whole-body distribution in rats incl. melanin-containing skin and eyes; ocular elimination ~40 days
“Radiolabeled [14C]‐fedratinib was distributed throughout the whole body of the rat, including to the skin and eyes (i.e. melanin‐containing tissues). Elimination from the eyes was approximately 40 days.”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗

Iqirvo

elafibranor · PPARα/δ
Immune & cytokine safety
Thymic atrophy in dogs from 30 mg/kg/day (females) and 100 mg/kg/day (males)
“Thymic atrophy was observed in female dogs starting from 30 mg/kg/day and in male dogs from 100 mg/kg/day.”
✓ VerifiedEMA assessment report, p. 33Source ↗
Biodistribution & persistence
Rat: highest in GI tract and liver, no tissue accumulation, cleared by 168 h
“No accumulation of radioactivity was observed in tissues or organs. The highest concentrations were measured in the digestive tract and liver, and no radioactivity was detected in any organ at 168 hours after administration.”
✓ VerifiedFDA integrated review, p. 182Source ↗

Isturisa

osilodrostat · 11β-hydroxylase (CYP11B1)
Immune & cytokine safety
Strong skin sensitizer (Category 1A) in murine local lymph node assay
“LCI699 was determined to be a strong sensitizing agent (Category 1A) indicating there is the potential for an allergic response following skin contact.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Biodistribution & persistence
Wide distribution, highest in adrenal, brain, kidney, liver, pancreas, spleen; melanin binding
“Osilodrostat is distributed into most tissues with the highest levels in the adrenal gland, brain, kidney, liver, pancreas, and spleen. LCI699 was found to bind melanin,”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗

Itovebi

inavolisib · PI3Kα (mutant-selective)
Immune & cytokine safety
Lymphoid depletion in dogs after 4 weeks of dosing
“Decreases in lymphocytes in lymphoid tissues were observed in dogs administered inavolisib for 4 weeks.”
✓ VerifiedEMA assessment report, p. 25Source ↗
Biodistribution & persistence
Higher radioactivity in melanin-containing uveal tract and skin of pigmented rats
“In pigmented rats, distribution of inavolisib-derived radioactivity was comparable to that in albino rats, with the exception of melanin containing tissues, such as uveal tract and skin that presented higher levels of radioactivity.”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗

Jascayd

nerandomilast · PDE4B
Immune & cytokine safety
IL-6 induction by high-dose PDE4 inhibition linked to rat mesenteric vasculitis
“An increased IL-6 expression (mRNA and protein) as a consequence of usage of high doses of pan-PDE4 inhibitors has been linked to the development of mesenteric vasculitis in rat [Dietsch 2006].”
✓ VerifiedEMA assessment report, p. 33Source ↗
Biodistribution & persistence
Fast, extensive tissue distribution; moderate binding to ocular melanin but not skin melanin
“Tissue distribution of radioactivity from whole blood into peripheral tissues appeared to be fast and extensive. In pigmented rats, there was moderate affinity of radioactivity to melanin-containing tissues of the eye, but no discernible affinity to melanin in the skin.”
✓ VerifiedEMA assessment report, p. 31Source ↗

Jaypirca

pirtobrutinib · BTK (non-covalent)
Immune & cytokine safety
Decreased B lymphocytes and TDAR response to KLH; adverse only for the anti-KLH TDAR in male rats
“Effects on immune system function consisted of a shift in the balance of T, B, and NK lymphocytes, largely due to a decrease in B lymphocytes, and decreased TDAR response to KLH, a foreign antigen. With the exception of the anti-KLH TDAR in male rats, these effects were not considered adverse due to the lack of effect on the overall well-being of the animals.”
✓ VerifiedEMA assessment report, p. 38Source ↗
Biodistribution & persistence
Radioactivity persisted in uveal tract and liver at 168 h (t1/2 66.4 and 56.1 h)
“The radioactivity declined over time to below the lower limit of quantitation (< 178 ng-eq) by 168 hours post dose for all tissues but the uveal tract and liver (294 and 262 ng-eq, respectively at 168 hours), with a calculated t1/2 of 66.4 and 56.1 hours, respectively.”
✓ VerifiedEMA assessment report, p. 28Source ↗

Jesduvroq

daprodustat · HIF prolyl hydroxylase
Immune & cytokine safety
Thymic lymphoid atrophy in the 13-week monkey study
“In monkeys, there were fewer organs of toxicity (only bone marrow [erythroid hypercellulartity], lung [alveolar hemorrhage], thymus [lymphoid atrophy], and stomach”
✓ VerifiedFDA integrated review, p. 245Source ↗
Biodistribution & persistence
Rat QWBA: uveal tract and pigmented skin radioactivity undetectable by Day 7; no irreversible melanin binding
“Radioactivity concentrations in the uveal tract, pigmented skin, and meninges peak at 1h or 4h declining steadily afterwards until undetectable by Day 7. This finding suggests no irreversible binding to melanin-containing tissues.”
✓ VerifiedFDA integrated review, p. 243Source ↗

Jideytro

zidesamtinib · ROS1
Immune & cytokine safety
Dose-dependent lymphoid depletion (GALT, lymph nodes, spleen, thymus) in dogs, incompletely reversible at 4 mg/kg/day
“Dogs had dose-dependent decreased cellularity of lymphoid tissues, including gut-associated lymphoid tissue (GALT), lymph nodes, spleen, and thymus, which did not completely resolve in the 4 mg/kg/day group.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Biodistribution & persistence
Rapid wide tissue distribution in rats (within 15 minutes), including male reproductive and melanin-pigmented tissues (uvea, skin)
“Following a single oral dose to rats, 14C-zidesamtinib distributed to nearly all tissues within 15 minutes. Radioactivity was detected in male reproductive tissues (seminal vesicle, prostate gland, epididymis, and testes) and melanin-pigmented tissues (uveal tract and skin).”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗

Joenja

leniolisib · PI3Kδ
Immune & cytokine safety
Lymphoid atrophy (lymph node, thymus, GALT) and immunosuppression-related skin lesions/infections in rats
“Treatment-related atrophy of the mesenteric lymph node, thymus, and GALT/Peyer’s patches were observed in male and female rats at all doses and attributed to immune suppression based on the pharmacology of leniolisib.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Biodistribution & persistence
Moderate tissue distribution with high skin affinity; highest in bile, hair follicle, liver, intestinal wall, kidney and melanin-containing structures
“In radioactive studies, leniolisib was moderately distributed into tissues (Vss of 1.06 L/kg in rats and 0.657 L/kg in monkeys) with a high skin affinity. After a single oral dose of 10 mg/kg to male rats, the highest exposures were found in the bile, hair follicle, liver, intestinal wall, kidney as well as in melanin-containing structures.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗

Journavx

suzetrigine · NaV1.8
Immune & cytokine safety
Not a skin sensitizer in the mouse local lymph node assay
“SUZ was not a skin sensitizer in a local lymph node assay in the mouse.”
✓ VerifiedFDA integrated review, p. 146Source ↗
Biodistribution & persistence
Reversible melanin binding: rat uveal tract, pigmented skin and meninges peaked at 1-4 h, undetectable by 72 h
“Radioactivity concentrations in melanin-containing tissues in rats (i.e., the uveal tract, pigmented skin, and meninges) peaked between 1 and 4 hours postdose then declined to undetectable levels by 72 hours postdose.”
✓ VerifiedFDA integrated review, p. 118Source ↗

Klisyri

tirbanibulin · Tubulin / Src
Immune & cytokine safety
Some skin sensitisation potential in guinea pig Buehler assay
“Tirbanibulin ointment exhibited some evidence of potential to induce sensitization when topically applied to the skin of guinea pigs in a Buehler assay.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Biodistribution & persistence
Rat oral QWBA: highest in plasma, liver, stomach, intestines, adrenals, kidneys and thyroid
“Activity achieved highest levels in plasma, liver, stomach, intestines, adrenals, kidneys, and thyroid.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗

Komzifti

ziftomenib · Menin-KMT2A
Immune & cytokine safety
Thymic white blood cell infiltration, vacuolation and lymphoid depletion, persisting after recovery
“Other target organs included the liver and the thymus, where white blood cell infiltration, vacuolation, and lymphoid depletion was noted microscopically. The microscopic findings persisted at the end of the recovery period.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Biodistribution & persistence
Melanin binding in uveal tract of pigmented mice, with elimination over time
“Distribution trends were similar across pigmented and nonpigmented strains, except that radioactivity was distributed in the uveal tract, indicating binding to melanin-containing tissues with evidence of elimination of radioactivity from melanin containing tissues over time.”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗

Koselugo

selumetinib · MEK1/2
Immune & cytokine safety
Secondary lymphoreticular changes with inflammatory/ulcerative GI findings in mice (~19.5x clinical free AUC)
“Inflammatory and ulcerative GI tract findings associated with secondary changes in the liver and lymphoreticular system at free exposures approximately 19.5 times the clinical free AUC at the MRHD were observed in mice.”
✓ VerifiedEMA assessment report, p. 43Source ↗
Biodistribution & persistence
Rat QWBA: highest in lung, liver, kidney and adrenal; no high-affinity melanin binding
“Relatively higher concentrations of radioactivity were found in the lung, liver, kidney and adrenal gland at each timepoint. There was no evidence of high affinity melanin-specific binding of radioactivity in the pigmented tissues (pigmented skin and uveal tract).”
✓ VerifiedFDA multi-discipline review, p. 53Source ↗

Krazati

adagrasib · KRAS G12C
Immune & cytokine safety
Lymphoid tissue changes not considered an immunotoxicity risk; no dedicated immunotoxicity studies
“It is further clarified that adagrasib-induced microscopic changes in lymphoid tissues, do not appear to translate into an immunotoxicity risk is supported. Omission of specific immunotoxicity studies is therefore accepted.”
✓ VerifiedEMA assessment report, p. 36Source ↗
Biodistribution & persistence
Distributed to nearly all rat tissues by 8 h; affinity for melanin-pigmented tissues
“Following single oral administration to rats, 14C-adagrasib-derived radioactivity distributed to nearly all tissues by 8 hours post-dose. Adagrasib demonstrated affinity for melanin-pigmented tissues.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗

Kygevvi

doxecitine and doxribtimine · Pyrimidine nucleoside replacement (TK2 deficiency)
Immune & cytokine safety
No hormonal or immune modulation in 26-week juvenile rat and 13-week dog studies
“In 26-week juvenile rat and 13-week dog studies, no evidence of tumorigenicity, hyperplasia, preneoplastic lesions, neoplasia, or hormonal/immune modulation was observed.”
✓ VerifiedEMA assessment report, p. 40Source ↗
Biodistribution & persistence
Not studied by the applicant; deoxynucleosides distribute extensively, highest in spleen, liver, kidney and intestine
“No pharmacokinetic studies on organ distribution were performed with exogenous doxecitine and doxribtimine, since sufficient data was available from literature. Exogenous deoxycytidine and deoxythymidine are distributed extensively in the body, with the highest levels in spleen, liver, kidney, and intestine.”
✓ VerifiedEMA assessment report, p. 37Source ↗

Lampit

nifurtimox · Trypanosoma cruzi
Immune & cytokine safety
Decreased thymus weights in high-dose rats without correlating histopathology
“Thymus: Mean absolute and relative thymus weights in HD male and female rats were decreased. The thymus weight changes were not accompanied by correlating histopathology.”
✓ VerifiedFDA multi-discipline review, p. 65Source ↗
Biodistribution & persistence
Extensive tissue distribution; highest in kidney and liver, also lung, adrenal, thyroid, testes, brain, spinal cord
“In a mass-balance study, [35S]nifurtimox was shown to extensively distribute to tissues, with the highest concentrations of radioactivity in the kidneys and liver followed by lung, adrenal and thyroid glands, testes, brain, and spinal cord.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗

Lazcluze

lazertinib · EGFR (mutant-selective)
Immune & cytokine safety
Skin sensitizer in mouse local lymph node assay
“Lazertinib was classified as a skin sensitizer in a local lymph node assay in mice, but did not meet the requirement for inducing serious eye damage in a bovine corneal opacity and permeability (BCOP) test.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Biodistribution & persistence
Melanin binding in uveal tract and pigmented skin
“Distribution of 14C-lazertinib-derived radioactivity in the uveal tract and pigmented skin indicated melanin binding.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗

Leqselvi

deuruxolitinib · JAK1/JAK2
Immune & cytokine safety
Reduced WBC and lymphocytes; lymphoid depletion in spleen, thymus, lymph nodes and GALT
“The target organs were identified as lymphoid organs in both species, with major study findings including reduced circulating white blood cells and lymphocytes and decreased lymphocytes/cellularity in various lymphoid tissues (including spleen, thymus, lymph nodes, and gut-associated lymphoid tissue).”
✓ VerifiedFDA multi-discipline review, p. 50Source ↗
Biodistribution & persistence
Excreted in rat milk; milk/plasma ratios ~7 to 20 over 8 hours
“Milk/plasma concentration ratios were approximately 7, 13, 19, and 20 at 1 hr, 2 hr, 4 hr, and 8 hr postdose, respectively.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗

Lifyorli

relacorilant · Glucocorticoid receptor (antagonist)
Immune & cytokine safety
Generalized lymphoid depletion contributed to deaths in 2-week rat studies at ≥200 mg/kg/day
“In the 2-week studies, mortality was noted following repeated doses ≥ 200 mg/kg/day in rats and doses ≥ 200/80 mg/kg/day in monkeys. In rats, the deaths were attributed to inappetence and generalized lymphoid depletion.”
✓ VerifiedFDA multi-discipline review, p. 51Source ↗
Biodistribution & persistence
Crosses the blood-brain barrier in mice and rats
“Relacorilant crossed the blood-brain barrier in both mice and rats (Studies S-COR-101 and S-COR-065).”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗

Litfulo

ritlecitinib · JAK3/TEC kinases
Immune & cytokine safety
Adverse immunosuppression (skin mites, lung inflammation) at 40 mg/kg/day in the 39-week dog study
“In the first 39-week oral RDT study in dogs with 3-month recovery (doses: 0, 5, 20, and 40 mg/kg/day), no ritlecitinib-related effects were noted on mortality, ECG, or ophthalmology. At the HD, ritlecitinib-related immunosuppression was adverse because of skin mites and lung inflammation.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Biodistribution & persistence
Poor blood-brain barrier penetration in rat (brain:plasma ~0.04); melanin-related accumulation in uveal tract
“However, the low brain: plasma AUC ratio at ~0.04 demonstrates that penetration of the blood-brain barrier is inefficient in the rat. The high AUC and long excretion T1/2 in the uveal tract suggest melanin-related accumulation.”
✓ VerifiedEMA assessment report, p. 33Source ↗

Livdelzi

seladelpar · PPARδ
Immune & cytokine safety
No immunotoxicity in repeat-dose studies; negative mouse local lymph node assay
“Seladelpar did not show potential for immunotoxicity in the repeat-dose toxicity studies and no sensitisation potential was recorded in the local lymph node assay in mouse.”
✓ VerifiedEMA assessment report, p. 34Source ↗
Biodistribution & persistence
Wide distribution in rats (QWBA), highest in liver, kidney and bladder
“Seladelpar was widely distributed in rats, as demonstrated by quantitative whole-body autoradiography (QWBA) data in both non-pigmented and pigmented rats with the highest radioactivity detected in the liver, kidney, and bladder.”
✓ VerifiedEMA assessment report, p. 37Source ↗

Livtencity

maribavir · CMV UL97 protein kinase
Immune & cytokine safety
Not immunotoxic in rats up to 100 mg/kg/day
“Maribavir was not immunotoxic in rats at up to 100 mg/kg/day.”
✓ VerifiedFDA integrated review, p. 77Source ↗
Biodistribution & persistence
Melanin binding: uveal tract radioactivity ~6-fold higher in pigmented rats, retained beyond 504 h
“In pigmented rats, concentrations of radioactivity in the uveal tract were approximately 6-fold higher than those observed for albino rats, and were measurable through the last timepoint, indicating retention of DRM beyond 504 hours postdose.”
✓ VerifiedFDA integrated review, p. 135Source ↗

Lumakras

sotorasib · KRAS G12C
Immune & cytokine safety
Decreased thymus weight and lymphoid cellularity in dogs
“pituitary gland (increased weight and hypertrophy of pituitary basophils of the pars distalis), thymus (decreased weight and decreased lymphoid cellularity), and gallbladder (bile sludge).”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Biodistribution & persistence
Wide distribution, highest in liver, kidney, thyroid, pancreas, lacrimal and adrenal glands; low brain penetration
“Following single oral administration, 14C-sotorasib-derived radioactivity distributed widely to rat tissues especially the liver, kidney, thyroid, pancreas, exorbital lacrimal gland, intra-orbital lacrimal gland, and adrenal gland, but brain penetration appeared low.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗

Lupkynis

voclosporin · Calcineurin
Immune & cytokine safety
Immunosuppression: thymic medullary atrophy, absent germinal centers, lymphomas, decreased lymphocytes
“In general, the adverse findings with the different proportions of cis:trans isomers of voclosporin were due to drug-related immunosuppression (e.g., thymic medullary atrophy, absence of germinal centers, lymphomas, decreased lymphocyte counts)”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Biodistribution & persistence
Low distribution to eye; negligible melanin binding
“Drug-derived radioactivity distributed to the eye (target tissue) following oral administration of 14C-voclosporin, although at low levels. The distribution profile of drug-derived radioactivity was similar in pigmented and non-pigmented rats, suggesting negligible binding of the drug and/or its metabolites to melanin.”
✓ VerifiedFDA multi-discipline review, p. 525Source ↗

Lybalvi

olanzapine and samidorphan · D2/5-HT2A; opioid receptors (samidorphan)
Immune & cytokine safety
Non-adverse, partially reversible thymus weight decrease with lymphoid depletion in male dogs
“Non-adverse, partially reversible decreases in thymus weights with corresponding microscopic findings of lymphoid depletion were observed in males only after treatment with OLZ, SAM, and the combination.”
✓ VerifiedFDA multi-discipline review, p. 447Source ↗
Biodistribution & persistence
Samidorphan highly distributed to tissues; binds melanin-containing tissues including skin and eyes
“SAM is highly distributed to tissues in rats and was found to bind to melanin-containing tissues including skin and eyes and is mainly excreted in urine in rats and dogs.”
✓ VerifiedFDA multi-discipline review, p. 445Source ↗

Lynkuet

elinzanetant · NK1/NK3 receptors
Immune & cytokine safety
Thymus atrophy and lymphoid depletion, attributed to treatment-induced stress
“In addition, thymus atrophy, reduced thymus weight or lymphoid depletion of the thymus were noted. The effects observed in adrenal glands and thymus were discussed to be related to treatment-induced stress and non-adverse.”
✓ VerifiedEMA assessment report, p. 33Source ↗
Biodistribution & persistence
Distributes to liver and pigmented tissues (uveal tract, retina); crosses the blood-brain barrier
“Autoradiographic studies revealed that, following the oral administration of radiolabeled elinzanetant to different species, radioactivity distributed to major organs, including the liver and pigmented tissues (e.g., the uveal tract and the retina). In typical PK studies, elinzanetant was also found to cross the blood brain barrier.”
✓ VerifiedFDA integrated review, p. 79Source ↗

Mayzent

siponimod · S1P1/S1P5 receptor
Immune & cytokine safety
Lymphoid depletion with reduced WBC and lymphocytes in all species, attributed to pharmacology
“Lymphoid tissues (depletion) were target organs in all species and was accompanied by decreased circulating levels of WBC and lymphocytes; this effect of siponimod was attributed to the pharmacological action of the drug.”
✓ VerifiedFDA pharmacology/toxicology review, p. 14Source ↗
Biodistribution & persistence
CNS penetration in rats: brain and spinal cord exposure 0.8- to 4.4-fold blood
“In rats, siponimod was detected in brain and CSF after oral administration. Siponimod exposures in brain and spinal cord were between 0.8- and 4.4-fold that in blood.”
✓ VerifiedFDA pharmacology/toxicology review, p. 26Source ↗

Miplyffa

arimoclomol · Heat-shock response amplifier
Immune & cytokine safety
Lymphoid and bone marrow depletion, spleen and thymus atrophy at MTD or higher
“Dosed at the maximum tolerated dose or higher, arimoclomol affected hematology parameters(e.g. reduced mean corpuscular volume, hemoglobin concentration and erythrocyte count), lymphoid and bone marrow depletion, and atrophy/reduced weight of the spleen and thymus.”
✓ VerifiedFDA integrated review, p. 199Source ↗
Biodistribution & persistence
Low-level distribution to skin, brain and eyes, eliminated within 24 hours
“Low level distribution of arimoclomol to the skin, brain and eyes was observed with elimination occurring within 24 hours.”
✓ VerifiedFDA integrated review, p. 201Source ↗

Myqorzo

aficamten · Cardiac myosin
Immune & cytokine safety
Guinea pig dermal sensitisation study (modified Buehler) negative: no erythema after topical application
“A sensitization Study of CK-3773274 by Dermal Administration in Guinea Pigs – Modified Buehler Design Negative, aficamten did not induce erythema after 48 hours of topical application.”
✓ VerifiedFDA integrated review, p. 131Source ↗
Biodistribution & persistence
Reversible melanin binding: higher levels in pigmented skin, prolonged retention in eye uveal tract
“Pigmented skin showed higher concentrations of radioactivity than nonpigmented skin, which, together with the prolonged presence of radioactivity in eye uveal tract, indicated (reversible) melanin binding.”
✓ VerifiedEMA assessment report, p. 28Source ↗

Nextstellis

drospirenone and estetrol · Estrogen / progestin receptors
Immune & cytokine safety
Thymus weight reduction with minimal to severe lymphoid atrophy in all species
“Lymphoid atrophy was noted in all species evaluated. Thymus weight was reduced in all species, associated with minimal to severe lymphoid atrophy.”
✓ VerifiedEMA assessment report, p. 29Source ↗
Biodistribution & persistence
Wide tissue distribution with rapid elimination; no retention, including in melanin-containing tissues
“E4 and its metabolites were widely distributed in rat tissues after a single oral dose of [14C]-E4 and are rapidly eliminated with no evidence of retention in any organ or tissues, including melanin-containing tissues.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗

Nourianz

istradefylline · Adenosine A2A receptor
Immune & cytokine safety
No antigenicity: no anaphylaxis (ASA/PCA) reactions or drug-specific antibodies
“Neither ASA nor PCA reactions were found and no specific antibodies to KW-6002 were detected. Under the conditions of this study, no antigenicity was determined with KW-6002.”
✓ VerifiedFDA pharmacology/toxicology review, p. 134Source ↗
Biodistribution & persistence
Placental and milk transfer; radioactivity higher and more persistent in fetuses and neonates than in dams
“In two studies of radiolabeled istradefylline in pregnant or nursing rats, the radioactivity persisted for a longer time and at higher levels in both fetuses and neonates than in dams.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗

Nubeqa

darolutamide · Androgen receptor
Immune & cytokine safety
Increased thymus weight in male rats and dogs, possibly reduced thymic involution; no immunotoxicity studies
“The corresponding microscopic findings included reduction of secretion in the prostate gland, vacuolation of the epididymal epithelium and a possible reduction in the normal involution of the thymus.”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Biodistribution & persistence
Wide distribution; low brain penetration (brain/plasma <0.05); reversible melanin binding; low blood-testis penetration
“In mice, darolutamide and keto-darolutamide and in rats total radioactivity exhibited low penetration into brain (brain/plasma ratio of AUC(0-24) < 0.05).”
✓ VerifiedEMA assessment report, p. 30Source ↗

Nulibry

fosdenopterin · cPMP replacement (MoCD type A)
Immune & cytokine safety
No antigenicity or immunotoxicity studies conducted
“No studies on antigenicity, immunotoxicity, dependence, or metabolites have been conducted.”
✓ VerifiedEMA assessment report, p. 25Source ↗
Biodistribution & persistence
Extensive distribution; highest in kidney, bone epiphyseal line, skin, liver and esophagus
“In both the pigmented and nonpigmented rats, the highest concentrations of fosdenopterin were observed in the kidney, bone epiphyseal line, skin, liver, and esophagus.”
✓ VerifiedFDA integrated review, p. 84Source ↗

Nurtec ODT

rimegepant · CGRP receptor
Immune & cytokine safety
No effects on the immune system in pivotal studies
“Further, no hormonal perturbation, histopathological changes in endocrine or reproductive organs or effects on the immune system were observed in pivotal non-clinical studies.”
✓ VerifiedEMA assessment report, p. 21Source ↗
Biodistribution & persistence
Wide extravascular distribution in pigmented and albino rats; likely melanin binding
“A single-dose tissue distribution study in pigmented and albino rats demonstrated that rimegepant is widely distributed extravascularly and likely binds to melanin.”
✓ VerifiedEMA assessment report, p. 23Source ↗

Nuzolvence

zoliflodacin · Bacterial topoisomerase II
Immune & cytokine safety
One male dog at 500 mg/kg/day euthanized with marked necrosis and inflammation of ileum and gut-associated lymphoid tissue
“One male dog administered 500 mg/kg/day AZ13420914 was euthanized early for low feed consumption and body weight loss. The cause of morbidity in this animal appeared to be due to marked necrosis and inflammation of the ileum and gut-associated lymphoid tissue.”
✓ VerifiedFDA integrated review, p. 131Source ↗
Biodistribution & persistence
Highest in kidney and liver in rats; no preferential distribution to pigmented tissues
“In an IV dosed tissue distribution study with radiolabeled zoliflodacin in rats, the highest levels were detected in kidneys and liver, and the zoliflodacin concentration was not higher in pigmented tissues.”
✓ VerifiedFDA integrated review, p. 69Source ↗

Ogsiveo

nirogacestat · Gamma secretase
Immune & cytokine safety
Decreased cellularity of gut-associated lymphoid tissue and mesenteric lymph nodes in rats
“In the 3‐month rat study, ovarian atrophy, alterations in the estrous cycle and decreased cellularity in gut‐associated lymphoid tissue (GALT) in females, and decreased cellularity of mesenteric lymph nodes in males and females at 5 mg/kg/day was observed.”
✓ VerifiedFDA multi-discipline review, p. 61Source ↗
Biodistribution & persistence
Highest in uveal tract, liver, adrenal, spleen, pituitary; binds melanin in pigmented ocular tissues
“Excluding excreta, the highest Cmax levels of radiolabeled [14C] nirogacestat were uveal tract, liver, adrenal gland, spleen, and pituitary gland. Radiolabeled [14C] nirogacestat exhibited an affinity for pigmented ocular tissues containing melanin.”
✓ VerifiedFDA multi-discipline review, p. 60Source ↗

Ojemda

tovorafenib · RAF (type II pan-RAF)
Immune & cytokine safety
Rat: minimal to mild thymus and mesenteric lymph node depletion, not reversed after recovery
“Effects on thyroid gland (follicular call atrophy), thymus and mesenteric lymph node (minimal to mild depletion) did not resolve at the end of the recovery period in the 3-month study.”
✓ VerifiedEMA assessment report, p. 40Source ↗
Biodistribution & persistence
Rat QWBA: crosses blood–brain barrier (brain/plasma AUC ≈0.6); reversible melanin binding
“Notably, brain exposure was measurable (brain/plasma AUC ≈ 0.6), supporting blood–brain barrier penetration adequate for the treatment of paediatric low-grade gliomas. Tovorafenib also demonstrates a reversible affinity for melanin-rich tissues, including pigmented skin, the uveal tract or substantia nigra.”
✓ VerifiedEMA assessment report, p. 36Source ↗

Ojjaara

momelotinib · JAK1/JAK2/ACVR1
Immune & cytokine safety
Hematopoietic and lymphoid tissue targets: bone marrow, spleen, lymph node and thymus
“Consistent with drug pharmacology as a JAK inhibitor, momelotinib targeted hematopoietic tissues, i.e., bone marrow, spleen, lymph node and thymus.”
✓ VerifiedFDA integrated review, p. 187Source ↗
Biodistribution & persistence
Low penetration across blood-brain and blood-testis barriers; not quantifiable in bone, brain, spinal cord, testis
“Radioactivity was nonquantifiable in bone, brain, spinal cord, and testis at all sampling times suggesting low penetration of 14C-MMB-derived radioactivity across the blood-brain and blood-testis barriers.”
✓ VerifiedEMA assessment report, p. 28Source ↗

Olinvyk

oliceridine · μ-opioid receptor (G-protein biased)
Immune & cytokine safety
Stress-related reductions in white blood cells and lymphocytes; minimal thymus atrophy
“Stress- or dehydration-related changes in clinical chemistry, hematology (such as reduced white blood cells and lymphocytes), and histopathology (such as increased hypertrophy of adrenal cortex corresponding to increased adrenal weight as well as minimal thymus atrophy) were observed across nonclinical studies”
✓ VerifiedFDA multi-discipline review, p. 163Source ↗
Biodistribution & persistence
Wide distribution in rats to liver, kidney, skin and skeletal muscle
“Total radioactivity (parent and metabolites) is distributed widely after IV dosing of oliceridine in rats, with 14C-concentrations found in well-perfused (liver, kidney) and poorly-perfused (skin, skeletal muscle) tissues.”
✓ VerifiedFDA multi-discipline review, p. 700Source ↗

Ongentys

opicapone · COMT
Immune & cytokine safety
Slight increase in T-helper lymphocytes in rats, with no functional change (sheep RBC response)
“In all dosed groups there was a slight increase in the Thelper (CD3+/CD4+)lymphocyte populations, with no alteration in function or response to sheep RBC’s.”
✓ VerifiedFDA pharmacology/toxicology review, p. 27Source ↗
Biodistribution & persistence
Rat QWBA: highest in liver and kidney; brain below limit of quantification
“the highest tissue levels were found in the liver, kidney cortex, and renal medulla (7163, 4243, and 3806 ng equiv/g, respectively). Concentrations in brain were found to be below the limit of quantification at all time points.”
✓ VerifiedFDA pharmacology/toxicology review, p. 17Source ↗

Orgovyx

relugolix · GnRH receptor
Immune & cytokine safety
No immunotoxicity studies; no immune-system findings in general toxicity studies
“Furthermore, there were no findings suggestive of effects on the immune system in general toxicity studies conducted in mice for up to 13 weeks, rats for up to 26 weeks, or monkeys for up to 39 weeks.”
✓ VerifiedFDA multi-discipline review, p. 65Source ↗
Biodistribution & persistence
Rat: highest in liver, intestine, thyroid, stomach, pituitary; radioactivity in melanin-rich eye tissues sustained up to 12 weeks
“Following a single oral dose of radiolabeled relugolix to rats, the highest radioactivity was observed in liver, intestine, thyroid, stomach and pituitary gland. Radioactivity in the eyes, mainly localized to the melanin rich tissues - anterior and posterior parts, was detected at 4 h and sustained for up to 12 weeks post-dose.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗

Orladeyo

berotralstat · Plasma kallikrein
Immune & cytokine safety
Foamy macrophages/histiocytes in spleen, thymus and intestine (phospholipidosis)
“Phospholipidosis-related findings included vacuoles in the epithelium and mucosa of the intestine, kidney, and choroid plexus (rats); foamy macrophages and histiocytes in the spleen, thymus, and intestine; and foamy Kupffer cells in the liver.”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗
Biodistribution & persistence
Binds melanin-containing tissues; highest late radioactivity in uveal tract of pigmented rats
“BCX7353 was found to bind to melanin-containing tissues. At 1440 hours post-dose, the highest concentration of radioactivity was quantified in the uveal tract of the eye.”
✓ VerifiedEMA assessment report, p. 32Source ↗

Orlynvah

sulopenem etzadroxil and probenecid · Penicillin-binding proteins
Immune & cytokine safety
Dose-related positive Coombs test in monkeys, likely antibody-mediated minimal erythrocyte loss
“Monkeys also exhibited positive Coombs test results that tended to increase with sulopenem etzadroxil dose and likely contributed to antibody mediation of minimal erythrocyte loss and compensatory erythropoiesis in monkeys.”
✓ VerifiedFDA integrated review, p. 260Source ↗
Biodistribution & persistence
Highest radioactivity exposure in kidney, liver, lung, skin, pancreas, spleen and blood
“The tissues with the highest AUC exposures to radioactivity over a period of 168 hours after dosing were in descending order: kidney, liver, lung, skin, pancreas, spleen, and blood.”
✓ VerifiedFDA integrated review, p. 265Source ↗

Orserdu

elacestrant · Estrogen receptor (SERD)
Immune & cytokine safety
Macrophage and neutrophilic infiltrates in mesenteric lymph node, lung and intestines of rats and monkeys
“Histopathology changes in rats and monkeys, other than those of the male and female reproductive organs (discussed below under fertility studies), were generally observations of increase in macrophage and/or neutrophilic infiltrates in mesenteric lymph node, lung, small and large intestines”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Biodistribution & persistence
Widespread tissue distribution in rats including ocular melanin (uveal tract); not detected in brain, lens, spinal cord or testes
“Following a single oral administration of elacestrant in rats, radiolabeled elacestrant was detected in the majority of tissues, including ocular melanin containing tissues (eye uveal tract of Long Evans rats), but not in the brain, eye lens, spinal cord, and testes”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗

Oxbryta

voxelotor · HbS polymerisation
Immune & cytokine safety
Immunosuppression: opportunistic infections in monkeys, reduced IgG/IgM titres, delayed antibody response
“2) The immunosuppressive action of voxelotor, manifested as increased mortality due to opportunistic infections in monkeys, significantly reduced IgG (rats, monkeys) and IgM (monkeys) titres, delayed antibody response (monkeys)”
✓ VerifiedEMA assessment report, p. 59Source ↗
Biodistribution & persistence
Crosses blood-brain barrier at ≥30-fold lower than blood; no melanin binding
“Radioactivity was found to cross the blood brain barrier, but exposure was at least 30-fold lower than in the blood. As pigmented and non-pigmented skin were similarly labelled, it is concluded that there is no melanin binding.”
✓ VerifiedEMA assessment report, p. 42Source ↗

Palsonify

paltusotine · Somatostatin receptor 2
Immune & cytokine safety
No dedicated immunotoxicity study; no immunotoxicity findings in the nonclinical or clinical program
“The Applicant has justified that no dedicated immunotoxicity study was performed, since no immune adverse effects are expected from the pharmacological properties. In addition, no immunotoxicity findings were observed in the non-clinical or clinical program.”
✓ VerifiedEMA assessment report, p. 36Source ↗
Biodistribution & persistence
Preferential melanin binding (meninges, uveal tract, pigmented skin); minimal brain penetration in rats
“Minimal brain to plasma ratio of paltusotine (<0.05) was observed in rats. QWBA study demonstrated a preferential binding to melanin containing tissues, namely the meninges, uveal tract, and the pigmented skin.”
✓ VerifiedEMA assessment report, p. 31Source ↗

Pemazyre

pemigatinib · FGFR1-3
Immune & cytokine safety
Multi-organ mononuclear cell infiltration in rats and monkeys
“Pemigatinib induced multi-organ histologic mononuclear cell infiltration in both species.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Biodistribution & persistence
Wide rat tissue distribution, especially excretory, endocrine, alimentary and pigmented tissues; minimal CNS
“Following single oral administration, 14C-pemigatinib-derived radioactivity distributed widely to rat tissues especially excretory, endocrine, alimentary canal, and pigmented tissues, but only minimally in CNS tissues.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗

Piqray

alpelisib · PI3Kα
Immune & cytokine safety
Inflammation and/or suppression in bone marrow, spleen, thymus and lymph nodes
“The effects in the hemolymphoid system included inflammation and/or suppressive effects in the bone marrow, spleen, thymus, or lymph nodes.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Biodistribution & persistence
Distribution to hair and eyes of pigmented rats; melanin binding
“Nonclinical ADME studies indicated distribution of radioactivity to hair and eyes of pigmented rats, thus alpelisib and/or its metabolites can bind melanin.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗

Ponvory

ponesimod · S1P1 receptor
Immune & cytokine safety
Reversible suppression of T-cell dependent antibody response during dosing
“The TDAR results suggest that there is immune suppression during the dosing of ponesimod that recovers when dosing is stopped.”
✓ VerifiedFDA pharmacology/toxicology review, p. 153Source ↗
Biodistribution & persistence
Wide tissue distribution; highest in GI tract and liver; brain and spinal cord above blood levels
“In albino rats, radioactivity was widely distributed into most tissues and was maximal at 1-4 hours post-dose. The highest exposures were found in GI tract and liver but was also observed in the brain and spinal cord at higher levels than blood at 1-4 hours post-dose.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗

Pretomanid

pretomanid · Mycobacterial cell wall / respiration
Immune & cytokine safety
Lymphoid depletion (spleen, thymus, Peyer's patches, BALT) in all three species, at toxic doses
“Signs of immunotoxicity were seen in most of the repeat-dose toxicity studies and in all three species, such as lymphoid depletion in the spleen, thymus, Peyer’s patches and bronchial-associated lymphoid tissue in the lungs, and alterations in lymphoid organ weights.”
✓ VerifiedEMA assessment report, p. 32Source ↗
Biodistribution & persistence
Rat: highest in Harderian gland, liver, kidney, adrenal, lacrimal gland and spinal cord
“In a study of radiolabeled PA-824 in rats, the highest tissue concentrations were measured in the Harderian gland, liver, renal medulla, adrenal gland, kidney, renal cortex, exorbital lacrimal gland, and spinal cord.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗

Qelbree

viloxazine · Norepinephrine reuptake
Immune & cytokine safety
Decreased thymus weight, considered secondary to stress and poor condition; reversible
“thymus with correlative decreased thymus weight in both sexes and arterial inflammation or degeneration in males. These findings were most likely secondary to the stress and poor condition of the animals, rather than a direct drug effect, and were reversible after recovery.”
✓ VerifiedFDA integrated review, p. 170Source ↗
Biodistribution & persistence
No skin accumulation; reversible melanin binding in the uveal tract with rapid elimination
“These data suggest that viloxazine or its metabolites do not preferentially distribute to or accumulate in the skin; viloxazine and its metabolites reversibly bind to melanin in the uveal tract but are rapidly dissociated or eliminated.”
✓ VerifiedFDA integrated review, p. 139Source ↗

Qinlock

ripretinib · KIT/PDGFRA
Immune & cytokine safety
Reduced thymus weight with decreased lymphocytes in dogs
“The weight of the thymus was reduced which correlated with the decreased number of lymphocytes observed microscopically.”
✓ VerifiedEMA assessment report, p. 29Source ↗
Biodistribution & persistence
Extensive, long-lived melanin binding in pigmented eye tissues (rat QWBA)
“Radiolabel associated with [14C]-ripretinib was extensively bound to melanin-containing tissues in pigmented LE rats such as eye ciliary body, eye uveal tract, and eyes, and the radiolabel binding showed a long half-life.”
✓ VerifiedEMA assessment report, p. 27Source ↗

Qulipta

atogepant · CGRP receptor
Immune & cytokine safety
ICH S8 weight-of-evidence review raised no immunotoxicity concerns
“The applicant has provided a weight of evidence review in accordance with ICH S8 which did not reveal any concerns.”
✓ VerifiedEMA assessment report, p. 26Source ↗
Biodistribution & persistence
Wide distribution in rats; negligible levels in CNS, eye and bone
“Most tissues had concentrations similar to those in blood, except for central nervous system tissues, eye and bone, which had negligible concentrations.”
✓ VerifiedEMA assessment report, p. 21Source ↗

Rapiblyk

landiolol · β1-adrenergic receptor
Immune & cytokine safety
Decreased thymus weight at the high dose in the rat fertility study
“Absolute and relative thymus weight was decreased at the high dose.”
✓ VerifiedFDA pharmacology/toxicology review, p. 63Source ↗
Biodistribution & persistence
Rat radiolabel: brain and fetal levels much lower than plasma; no brain radioactivity after repeat dosing
“Radioactivity levels in the brain and fetuses were much lower than that of plasma; drug-related radioactivity was not observed in the brain after repeat dosing.”
✓ VerifiedFDA pharmacology/toxicology review, p. 20Source ↗

Rasonque

daraxonrasib · RAS(ON) multi-selective
Immune & cytokine safety
Monkey immune activation with fibrinogen elevation, thymic toxicity and myelosuppression
“Findings included GI toxicity, myelosuppression, thymic toxicity, electrolyte imbalance, and immune activation (elevated fibrinogen was secondary to immune activation).”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Biodistribution & persistence
Mouse QWBA: widespread distribution, highest in tissues of excretion and elimination
“In a mouse QWBA study, distribution of [14C]-daraxonrasib was widespread with the highest concentrations of radioactivity generally associated with tissues involved in excretion and elimination.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗

Retevmo

selpercatinib · RET
Immune & cytokine safety
Hematopoietic and lymphoid system changes
“Similar findings included: changes in hematopoietic, lymphoid, and GIT systems, liver and altered inorganic phosphorus levels (hyperphosphatemia).”
✓ VerifiedFDA multi-discipline review, p. 80Source ↗
Biodistribution & persistence
Rat QWBA: highest in uveal tract, eyes, Harderian gland, meninges and melanin-containing skin
“Tissues from male rats that received 10 mg/kg [14C]-labeled selpercatinib showed the highest levels in uveal tract (24 hours post-dose), eyes (24 hr), Harderian gland (2 hr), meninges (72 hr), and pigmented (melanin-containing) skin (8 hr).”
✓ VerifiedFDA multi-discipline review, p. 78Source ↗

Revtorpyk

gedatolisib · PI3K/mTOR
Immune & cytokine safety
Decreased white blood cells and lymphocytes, reduced bone marrow cellularity (rat) and lymphocyte depletion in thymus and spleen
“Hematological changes were generally more pronounced in rats than dogs and included decreases in absolute white blood cells, reticulocytes, lymphocytes, monocytes, eosinophils, and basophils with microscopic correlates of decreased hematopoietic cellularity in bone marrow (rat), decreased lymphocytes in thymus (rat and dog), and spleen (dog).”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Biodistribution & persistence
Prolonged retention in pigmented tissues of rats: up to 672 hours in uveal tract and 96 hours in pigmented skin
“Following IV administration of [14C] gedatolisib to pigmented male and female rats, radioactivity was highly concentrated and retained for a prolonged period for up to 672 hours and 96 hours in the uveal tract of the eye and pigmented skin, respectively.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗

Revuforj

revumenib · Menin-KMT2A
Immune & cytokine safety
Lymphoid atrophy with decreased thymus weights in dogs at all doses
“Decreased thymus weights correlated with lymphoid atrophy in males and females at all doses.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Biodistribution & persistence
Rat eye uveal tract radioactivity peaked at 168 h and was sustained through 672 h
“The eye uveal tract had a Cmax of 19,500 ng eq/g at 168 hours post-dose at concentrations that were sustained through 672 hours post-dose.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗

Reyvow

lasmiditan · 5-HT1F receptor
Immune & cytokine safety
Splenic marginal-zone lymphoid depletion and thymic involution at high dose in rats
“In all HD animals, hepatocellular hypertrophy, foamy alveolar macrophages, epithelial vacuolation in the seminal vesicle, vacuolation and lymphoid depletion of the marginal zone in the spleen, cortical hypertrophy of the adrenals, decreased hematopoietic tissue in the bone marrow, and thymic involution were also observed”
✓ VerifiedFDA pharmacology/toxicology review, p. 31Source ↗
Biodistribution & persistence
Crosses blood-brain barrier (brain:plasma ~3); highest concentrations in urinary bladder and uveal tract
“Distribution studies (with [14C]lasmiditan) in rat show that lasmiditan crosses the blood brain barrier, with brain to plasma ratios of approximately 3 over a 24-hour period after IV dosing. The highest concentrations of [14C]lasmiditan were found in the urinary bladder and uveal tract of the eye.”
✓ VerifiedFDA pharmacology/toxicology review, p. 19Source ↗

Rezdiffra

resmetirom · Thyroid hormone receptor β
Immune & cytokine safety
Increased spleen weight in female mice without other immune findings; immunotoxicity risk low
“Resmetirom induced an increase in spleen weight of female mice at 3 and 100 mg/kg/day dose, however since correlation with other immune-related finding was not observed, the risk of immunotoxicity was considered low.”
✓ VerifiedEMA assessment report, p. 41Source ↗
Biodistribution & persistence
Liver ~10x and renal cortex ~3x plasma AUC; no melanin association in pigmented rats
“Liver AUC and renal cortex AUC for total radioactivity after dosing with [14C]MGL-3196 were approximately 10 times and 3 times the plasma AUC value, respectively. [14C]MGL-3196-related radioactivity was not specifically associated with the melanin-containing tissues in the pigmented LE rats.”
✓ VerifiedFDA integrated review, p. 224Source ↗

Rezlidhia

olutasidenib · IDH1 (mutant)
Immune & cytokine safety
Lymph node cellular depletion and increased white blood cells
“hematopoietic system (reduced RBCs and lineages, increased WBCs and differentials, increased platelets, and lymph node cellular depletion).”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Biodistribution & persistence
Highest QWBA levels in small intestine, cecum and liver; crosses blood-brain barrier in rats
“A QWBA distribution study in rats demonstrated tissues with the highest radioactivity concentrations were small intestines, cecum, and liver. Olutasidenib crossed the blood brain barrier in rats with unbound ratios of cerebrospinal fluid to plasma and brain to plasma of 0.29 and 0.1, respectively.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗

Rezurock

belumosudil · ROCK2
Immune & cytokine safety
Thymic lymphoid depletion with reduced thymus weight at high dose; not seen after recovery
“In addition, reduced thymus weights correlated with increased incidence and/or severity of thymic lymphoid depletion in HD males and females. Thymic lymphoid depletion was not observed in recovery males or females.”
✓ VerifiedFDA multi-discipline review, p. 72Source ↗
Biodistribution & persistence
No appreciable brain radioactivity; melanin binding (uveal tract, pigmented skin)
“All tissues demonstrated clearance and no appreciable radioactivity was observed in the brain. Melanin-containing tissues (uveal tract and pigmented skin) demonstrated higher tissue retention, indicating some affinity of belumosudil for melanin.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗

Rezzayo

rezafungin · Fungal glucan synthase
Immune & cytokine safety
Acute transient histamine-release response in rats; mild histamine-like response in monkeys
“Rezafungin induced an acute transient histamine-release response in rats. In monkeys, both the vehicle and rezafungin induced a mild transient histamine-like response in some studies.”
✓ VerifiedUS prescribing informationSource ↗
Biodistribution & persistence
Widespread distribution in rat; tissue exposure ~4-fold plasma in kidney, lung, liver, spleen, lower in heart and brain
“Tissue distribution was evaluated in rats after IV administration of rezafungin, demonstrating widespread exposure in various organs, with tissue/plasma AUC ratios that were comparable (approximately 4-fold higher in tissue than plasma) for major (kidney, lung, liver, spleen) organs with the exception of the heart and brain.”
✓ VerifiedEMA assessment report, p. 27Source ↗

Rhapsido

remibrutinib · BTK
Immune & cytokine safety
Inhibited primary antibody responses to some antigens, attributed to BTK role in B cells
“Remibrutinib inhibited primary antibody responses to certain, but not all, tool antigens in rodent pharmacology studies at pharmacologically relevant exposure, considered related to the role of BTK in B cells.”
✓ VerifiedEMA assessment report, p. 41Source ↗
Biodistribution & persistence
Broad tissue distribution except brain, eye lens, spinal cord and white fat
“A single oral dose of remibrutinib resulted in broad distribution in all tissues except for the brain, lens of the eye, spinal cord, and white fat, with a Tmax of 0.5 to 8 hours.”
✓ VerifiedFDA integrated review, p. 123Source ↗

Rinvoq

upadacitinib · JAK1
Immune & cytokine safety
Decreased circulating lymphocytes and lymphoid depletion in spleen, thymus and lymph nodes (JAK inhibition)
“The findings included decreases in circulating lymphocytes and lymphoid depletion in spleen, thymus, and lymph nodes.”
✓ VerifiedEMA assessment report, p. 28Source ↗
Biodistribution & persistence
Rat QWBA: not measurable in CNS or lens; prolonged uveal tract and pigmented skin retention (melanin affinity)
“Radioactivity concentrations were below measurable levels in the CNS tissues and the lens of the eye at all collection times throughout the study. Radioactivity was present in the uveal tract through 192 hours postdose and a slower clearance in pigmented skin indicating an apparent affinity for melanin.”
✓ VerifiedEMA assessment report, p. 25Source ↗

Romvimza

vimseltinib · CSF1R
Immune & cytokine safety
Rat: bone marrow suppression and lymphoid tissue hypocellularity/necrosis at the highest 28-day dose
“In rats, dose-limiting toxicity included bone marrow suppression, lymphoid tissue hypocellularity and/or necrosis at the highest dose tested in the 28-day study leading to termination of all animals for welfare reasons.”
✓ VerifiedEMA assessment report, p. 41Source ↗
Biodistribution & persistence
Rat QWBA: prolonged retention in uveal tract, eye and meninges to 672 h, suggesting melanin binding
“Radioactivity was cleared from most tissues by 168 hours post dose, but was still quantifiable in the meninges, eye uveal tract, eye(s), and eye vitreous humour at 672 hours, suggesting melanin binding.”
✓ VerifiedEMA assessment report, p. 27Source ↗

Rozlytrek

entrectinib · TRK/ROS1/ALK
Immune & cytokine safety
Lymphoid depletion in rat spleen (≥25 mg/kg/day), lymph nodes and thymus (≥200 mg/kg/day)
“Lymphoid depletion was observed at ≥25 mg/kg/day in the 4-week study in spleen, and also in lymph nodes and thymus at ≥200 mg/kg/day in the 4-week 2x2 intermittent dosing and 14-day studies.”
✓ VerifiedEMA assessment report, p. 55Source ↗
Biodistribution & persistence
Brain-penetrant: steady-state brain-to-plasma ratios ~0.4 (mouse), 0.6–1.5 (rat), 1.4–2.2 (dog)
“In addition, after repeated oral doses brain-to-plasma concentration ratios of entrectinib were higher at 24 hours post last dose in mice (~0.4), rats (0.6–1.5), and dogs (1.4-2.2), indicating brain penetration occurred under steady-state conditions.”
✓ VerifiedEMA assessment report, p. 66Source ↗

Rukobia

fostemsavir · HIV-1 gp120 (attachment)
Immune & cytokine safety
No immunotoxicity in TDAR assay within the 26-week rat study
“The potential effects of FTR on the T-cell dependent antibody response (TDAR) to KLH were evaluated in accordance with ICH S8 as part of the pivotal 26-week oral rat toxicity study. From this study there is no indication of an immunotoxic potential for FTR.”
✓ VerifiedEMA assessment report, p. 25Source ↗
Biodistribution & persistence
Melanin-associated uveal distribution; significant placental transfer with fetal exposure including brain
“These findings suggest a potential association with melanin containing tissues of the eye uveal tract. Distribution studies performed in pregnant rats revealed significant transfer across the placenta with foetal exposure to all tissues examined including the brain.”
✓ VerifiedEMA assessment report, p. 22Source ↗

Scemblix

asciminib · BCR-ABL1 (STAMP, myristoyl pocket)
Immune & cytokine safety
Thymic lymphocyte necrosis and splenic lymphoid depletion in one rat at 200 mg/kg/day
“necrosis of thymus lymphocytes, lymphoid depletion in spleen, lesions in the GI (ulceration and inflammation) in one rat at 200 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 52Source ↗
Biodistribution & persistence
Melanin binding; little blood-brain barrier penetration (brain/blood Cmax ratio 0.0149)
“Melanin binding of asciminib was observed. The brain tissue/blood Cmax ratio of 0.0149 indicated little penetration of the blood-brain barrier.”
✓ VerifiedEMA assessment report, p. 26Source ↗

Sephience

sepiapterin · Tetrahydrobiopterin precursor
Immune & cytokine safety
No immune-system effects in repeat-dose studies; no immunotoxicity studies
“No immunotoxicity assessments were performed as no sepiapterin-related effects on the immune system were observed in repeat-dose mammalian toxicology studies.”
✓ VerifiedEMA assessment report, p. 48Source ↗
Biodistribution & persistence
Low, non-retained distribution to melanin-containing tissues (meninges, uveal tract); no melanin association
“Distribution of radioactivity to certain melanin-containing tissues, such as the meninges and uveal tract was low and there was no extended retention, indicating that [14C]-sepiapterin-derived radioactivity was most likely not associating with melanin in these tissues.”
✓ VerifiedEMA assessment report, p. 33Source ↗

Skyclarys

omaveloxolone · Nrf2 activator
Immune & cytokine safety
No dedicated immunotoxicity studies; not required for this small molecule
“Considering the type of molecule (small molecule), investigations of antigenicity and immunotoxicity are not required for omaveloxolone.”
✓ VerifiedEMA assessment report, p. 36Source ↗
Biodistribution & persistence
~3.41% oral bioavailability in monkey; wide tissue distribution including brain, highest in GI tract
“Following oral administration to monkeys, [14C]RTA 408 was approximately 3.41% bioavailable and was widely distributed to most tissues, including brain, between 8 and 30 h, with the highest concentrations observed in the gastrointestinal tract.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗

Sofdra

sofpironium · Muscarinic receptors (topical)
Immune & cytokine safety
Skin irritant but not a skin sensitizer
“Sofpironium bromide is a skin irritant but not a sensitizer.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗
Biodistribution & persistence
Rat: low placental transfer; drug or metabolites excreted into milk
“The transfer of 14C-sofpironium and/or its metabolites across the placental barrier is low during both organogenesis (12th day of pregnancy) and late (18th day) pregnancy. Sofpironium or its metabolites were transferred into the milk after a single subcutaneous administration of 0.5 mg/kg to lactating rats on postpartum Day 10.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗

Sohonos

palovarotene · RARγ
Immune & cytokine safety
No evidence of immunosuppression
“No evidence of hormonal effects or immunosuppression”
✓ VerifiedFDA integrated review, p. 288Source ↗
Biodistribution & persistence
Slow but extensive tissue distribution (autoradiography)
“In autoradiography tissue distribution studies, palovarotene exhibited a slow but extensive distribution into the tissues.”
✓ VerifiedFDA integrated review, p. 277Source ↗

Sotyktu

deucravacitinib · TYK2
Immune & cytokine safety
Immunosuppression: lower lymphocyte counts, lymphoid depletion and reduced TDAR to KLH in rats; reduced TDAR in monkeys
“In rats, dose-dependent minimally to moderately decreased lymphocyte counts (including total T, helper T, cytotoxic T, B, and NK cells) generally correlated with decreased spleen and thymus size and weights, decreased lymphoid cellularity in lymph nodes, thymus and splenic white pulp, and decreased TDAR to KLH-specific IgM and IgG responses.”
✓ VerifiedEMA assessment report, p. 27Source ↗
Biodistribution & persistence
Substantial but reversible melanin binding (eye uveal tract), not in pigmented skin
“In pigmented rats, there was substantial, but reversible binding of [14C]BMS-986165-derived radioactivity to certain melanin-containing tissues, such as the eye uveal tract, but not in pigmented skin.”
✓ VerifiedEMA assessment report, p. 25Source ↗

Sunlenca

lenacapavir · HIV-1 capsid
Immune & cytokine safety
Positive in two of three in vitro skin sensitisation assays; negative in vivo
“Using in vitro skin models, lenacapavir was not considered corrosive but was considered positive in two of three skin sensitization assays. However, in the in vivo assessment, lenacapavir was considered negative for sensitization potential.”
✓ VerifiedFDA integrated review, p. 271Source ↗
Biodistribution & persistence
Rat QWBA: distribution restricted by blood-brain and blood-testes barriers
“No quantifiable or low levels of radioactivity were detected in brain and testes, respectively, suggesting that distribution of [14C]-lenacapavir-derived radioactivity was restricted by the blood to brain and blood-to-testes barriers.”
✓ VerifiedEMA assessment report, p. 22Source ↗

Sunosi

solriamfetol · Dopamine/norepinephrine reuptake
Immune & cytokine safety
Dose-dependent changes in immune cell counts and immune organ weight/morphology, most prominent in rats
“Concerning the immune system, dose-dependent effects of solriamfetol on numbers of immune cells and morphology/weight of immune-system related organs (most prominent in rat studies) were observed.”
✓ VerifiedEMA assessment report, p. 40Source ↗
Biodistribution & persistence
Extensive distribution into pigmented and non-pigmented tissues, including brain
“After oral administration, solriamfetol was extensively distributed into pigmented and non-pigmented tissues, including the brain.”
✓ VerifiedFDA pharmacology/toxicology review, p. 10Source ↗

Tabrecta

capmatinib · MET
Immune & cytokine safety
No specific immunotoxicity studies conducted
“No specific immunotoxicity studies were conducted with capmatinib”
✓ VerifiedEMA assessment report, p. 27Source ↗
Biodistribution & persistence
Reversible melanin binding (eye choroid); highest accumulation in eye lens and adrenal medulla
“In pigmented rats, radioactivity was reversibly distributed into the melanin containing structures such eye choroid. The highest accumulation was observed in eye (lens) and adrenal (medulla).”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗

Tavneos

avacopan · C5a receptor (C5aR1)
Immune & cytokine safety
No effect on monkey TDAR, peripheral immunophenotyping or lymphoid organ histology
“In monkeys, avacopan had no effect on T-cell dependent antibody responses or on relative or absolute values for peripheral blood immunophenotyping (total T lymphocytes, helper T lymphocytes, cytotoxic T lymphocytes, B lymphocytes, or natural killer cells).”
✓ VerifiedEMA assessment report, p. 25Source ↗
Biodistribution & persistence
Rat QWBA: slowly reversible association with melanin-containing tissues of the eye
“Distribution trends in the pigmented uveal tract suggested that [14C]-avacopan-related radioactivity associated with the melanin-containing tissues of the eye; this association was slowly reversible.”
✓ VerifiedEMA assessment report, p. 20Source ↗

Tazverik

tazemetostat · EZH2
Immune & cytokine safety
Monkey: lymphoid hyperplasia in mesenteric lymph node of a single male at 600 mg/kg/day
“In addition, lymphoid hyperplasia occurred in the mesenteric lymph node of a single male dosed at 600 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Biodistribution & persistence
CNS tissues below quantifiable levels
“Tissues of the CNS were below quantifiable levels.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗

Tepmetko

tepotinib · MET
Immune & cytokine safety
No immunotoxic potential in rat and dog repeat-dose studies
“Data collected from repeat-dose toxicity studies in rats and dogs, including haematology and clinical chemistry investigations, absolute and relative weights and histopathology of lymphoid organs were not indicative for an immunotoxic potential of tepotinib.”
✓ VerifiedEMA assessment report, p. 29Source ↗
Biodistribution & persistence
Rat QWBA: liver, lungs, kidneys, lymph nodes; eye and skin retention suggesting melanin binding
“In the remaining body, highest concentrations of radioactivity were detected in the liver, lungs, and kidneys and, 24 hours after administration, in the lymph nodes. In pigmented animals, medium levels of radioactivity were found in the eyes and skin throughout the investigational period of 96 hours”
✓ VerifiedEMA assessment report, p. 24Source ↗

Trikafta

elexacaftor, tezacaftor and ivacaftor · CFTR
Immune & cytokine safety
Lymphoid depletion in the thymus
“Microscopic correlates consisted of cortical hypertrophy/vacuolation in the adrenal glands, atrophy in the prostate, secretory depletion in the seminal vesicles/coagulating glands, germ cell debris/oligospermia in the epididymides, and lymphoid depletion in the thymus.”
✓ VerifiedEMA assessment report, p. 43Source ↗
Biodistribution & persistence
Elexacaftor crosses blood-brain barrier (brain ~3-fold below plasma); no preferential melanin binding
“VX-445-related radioactivity crossed the blood-brain barrier, but measured concentrations in the brain were about 3-fold lower relative to plasma. A tissue distribution study in Long-Evans rats showed no significant distribution to melanin-containing tissues (skin, eyes), indicating that VX-445 did not preferentially associate with melanin.”
✓ VerifiedEMA assessment report, p. 39Source ↗

Truqap

capivasertib · AKT1-3
Immune & cytokine safety
Decreased white blood cells and lymphocytes in rats
“Administration of capivasertib to rats resulted in increases in AST, ALT and GLDH, decreases in white blood cells and lymphocytes, increases in TSH”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Biodistribution & persistence
Reversible melanin binding in skin and uveal tract, persisting up to 168 h (skin) and 504 h (eye)
“Capivasertib was reversibly bound to melanin with persistence up to 168 h in the skin and 504 h in the eyes.”
✓ VerifiedEMA assessment report, p. 36Source ↗

Tryptyr

acoltremon · TRPM8 agonist
Immune & cytokine safety
Not a skin sensitizer in mouse local lymph node assay
“The product was not a sensitizer in the local lymph node assay performed with CBA/Ca mice at up to 50% acoltremon applied on the dorsal surface of both ears once daily (25 µL/dose) for 3 days consecutively.”
✓ VerifiedFDA integrated review, p. 77Source ↗
Biodistribution & persistence
Rabbit ocular distribution: detected only in conjunctiva (2/8 eyes); other ocular tissues below LLOQ
“in an ocular distribution study in the rabbit where animals received 3 µg/eye/day (1.67-fold the therapeutic dose) for 28 days, acoltremon was detected in the conjunctiva of 2 out of 8 eyes, while cornea, conjunctiva, aqueous humor, iris/ciliary body, vitreous humor, and retina were below the LLOQ of 5.05 ng/mL in all animals.”
✓ VerifiedFDA integrated review, p. 76Source ↗

Tukysa

tucatinib · HER2
Immune & cytokine safety
Lymphoid depletion (hemolymphoid system) in rats
“Additional target organs in rats included the hemolymphoid system (lymphoid depletion), male and female reproductive organs, and skeletal muscle (myofiber degeneration/regeneration and hemorrhage) in male rats in the 28-day study.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Biodistribution & persistence
Rat: highest in uveal tract, eyes, pigmented skin, liver, testes; not detected in CNS
“the highest distribution of tucatinib in rats was in the uveal tract, eyes, pigmented skin, liver, testes, epididymis (male), and thymus (female); tucatinib was not detected in CNS tissues.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗

Turalio

pexidartinib · CSF1R
Immune & cytokine safety
Thymic lymphoid depletion with decreased thymus weight and lymphocytes; lymphoid hyperplasia with lymph node enlargement
“Pexidartinib-related observations on the lymph/hematopoietic compartments include lymphoid depletion of the thymus with decreased thymus weight and lymphocyte counts and lymphoid hyperplasia with lymph node enlargement and increases in neutrophils and large unstained cells (LUC).”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Biodistribution & persistence
Highest exposure in uveal tract, liver, pancreas, Harderian gland and eye; still present in uveal tract at 336 h
“Tissues with the highest exposure (Cmax) to pexidartinib were the uveal tract, liver, pancreas, Harderian gland, and the entire eye. At the last sampling time of 336 hours post-dose, pexidartinib was still present in the eye including the uveal tract.”
✓ VerifiedFDA multi-discipline review, p. 47Source ↗

Ukoniq

umbralisib · PI3Kδ / CK1ε
Immune & cytokine safety
Decreased white blood cells and lymphoid depletion
“Drug-related findings included decreased white blood cells (WBCs) and differentials, increased liver weights and alkaline phosphatase (ALP) levels, and lymphoid depletion.”
✓ VerifiedFDA multi-discipline review, p. 29Source ↗
Biodistribution & persistence
Wide distribution in mice; lowest concentration in brain, limited CNS passage
“In mice, umbralisib was widely distributed, with the highest concentrations in the gastrointestinal, metabolic/excretory, fatty, secretory, and endocrine tissues and the lowest concentration in brain, demonstrating penetration of umbralisib occurred in richly perfused organs, while passage to the CNS was limited.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗

Utebzi

tebipenem pivoxil · Penicillin-binding proteins
Immune & cytokine safety
Negative in guinea pig delayed hypersensitivity and mouse/guinea pig antigenicity studies
“Orally administered tebipenem pivoxil was negative in a delayed hypersensitivity study using guinea pigs and in antigenicity studies in mice and guinea pigs.”
✓ VerifiedFDA integrated review, p. 225Source ↗
Biodistribution & persistence
Rat QWBA: extensive distribution except brain medulla, spinal cord, abdominal fat and eye lens
“Tissue distribution of radiolabeled tebipenem pivoxil was evaluated using quantitative whole-body autoradiography in male rats and showed extensive quantifiable levels of radioactivity measured in most analyzed tissues, with the exception of the brain medulla, spinal cord, abdominal fat, and eye lens.”
✓ VerifiedFDA integrated review, p. 329Source ↗

Vafseo

vadadustat · HIF prolyl hydroxylase
Immune & cytokine safety
No immunotoxic signals in rat and dog repeat-dose studies; no dedicated immunotoxicity studies
“It is considered acceptable that no information has been submitted on immunotoxicity as no relevant findings have been observed in the repeat-dose toxicity studies in rats and dogs to indicate an immunotoxic potential.”
✓ VerifiedEMA assessment report, p. 34Source ↗
Biodistribution & persistence
Crosses the placenta into fetal tissues and is secreted into milk (rat)
“Administered to pregnant rats and lactating rats, vadadustat related compounds were detected in the fetal tissues and the milk, demonstrating that vadadustat can cross placental tissues and can be delivered to newborns via nursing.”
✓ VerifiedFDA integrated review, p. 377Source ↗

Vanflyta

quizartinib · FLT3
Immune & cytokine safety
Hematologic and lymphoid toxicities from exaggerated pharmacology
“Hematologic and lymphoid toxicities were common and attributable to exaggerated pharmacology.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Biodistribution & persistence
Melanin binding: pigmented skin accumulated ~9-fold more radioactivity than non-pigmented skin
“Binding to melanin was evident as pigmented skin accumulated about 9-fold more radioactivity than non-pigmented skin.”
✓ VerifiedEMA assessment report, p. 26Source ↗

Vanrafia

atrasentan · Endothelin A receptor
Immune & cytokine safety
No immunosuppressive effect in 6-month rat and 9-month dog studies
“In addition, the repeat-dose toxicology studies in rats for up to 6 months and in dogs for up to 9 months do not suggest an immunosuppressive effect of atrasentan.”
✓ VerifiedFDA integrated review, p. 133Source ↗
Biodistribution & persistence
Rat: low levels in testes, eyes, bone marrow and fat; not detected in brain
“Low concentrations were observed in testes, eyes, bone marrow, and fat. Radioactivity was not detected in the brain.”
✓ VerifiedFDA integrated review, p. 116Source ↗

Veklury

remdesivir · SARS-CoV-2 RNA polymerase
Immune & cytokine safety
No dedicated immunotoxicity studies; no concerns in repeat-dose studies
“No dedicated immunotoxicity studies have been performed with remdesivir. This is considered acceptable as no concerns were identified by standard assessments in repeat-dose toxicology studies.”
✓ VerifiedEMA assessment report, p. 42Source ↗
Biodistribution & persistence
Crosses blood-testis barrier; eliminated from most tissues by 96 h; no melanin binding
“Low levels of radioactivity were detected in testes, suggesting [14C]remdesivir-derived radioactivity crossed the blood to testes barrier. Radioactivity was eliminated from majority of the tissues by 96 hours postdose in both SD and LE rats. No melanin binding was observed.”
✓ VerifiedEMA assessment report, p. 37Source ↗

Velsipity

etrasimod · S1P1/S1P4/S1P5 receptors
Immune & cytokine safety
Dose-dependent lymphocyte decreases in rats and dogs; lymphoid depletion in rat lymph nodes and spleen (pharmacological)
“Dose-dependent decreases in circulating lymphocytes were observed in both rats and dogs and correlated with lymphoid depletion in the lymph nodes and spleen of rats only; these findings were attributed to the pharmacological activity of etrasimod and not considered adverse.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Biodistribution & persistence
Wide distribution incl. GI tract, liver, kidney, myocardium, adrenal, thyroid, brain and spinal cord
“[14C]etrasimod distributed to tissues of GI tract, organs of clearance (kidney and liver), myocardium, secretory glands (adrenal and thyroid), and the non-circumventricular central nervous system tissues (spinal cord and brain) in non-pigmented and pigmented rats.”
✓ VerifiedEMA assessment report, p. 28Source ↗

Veozah

fezolinetant · Neurokinin-3 receptor
Immune & cytokine safety
No antigenicity or immunotoxicity studies conducted (not considered necessary)
“No antigenicity and immunotoxicity studies have been conducted with fezolinetant since these studies were not considered necessary.”
✓ VerifiedEMA assessment report, p. 33Source ↗
Biodistribution & persistence
Highest tissue levels in kidney cortex, clitoris, uveal tract/retina, adrenal gland and liver
“The highest levels of fezolinetant in tissues were associated with the kidney cortex, clitoris, uveal tract/retina, adrenal gland (cortex and medulla) and liver.”
✓ VerifiedFDA pharmacology/toxicology review, p. 19Source ↗

Verquvo

vericiguat · Soluble guanylate cyclase
Immune & cytokine safety
No indicators of immune-system effects; no further immunotoxicity evaluation
“As there were no indicators of effects on the immune system, no further specific evaluation was conducted.”
✓ VerifiedFDA integrated review, p. 170Source ↗
Biodistribution & persistence
Melanin binding, including substantia nigra, with longer half-lives in melanin-containing tissues
“Melanin binding of vericiguat and/or its metabolites was also observed for the substantia nigra. Elimination occurred with longer terminal half-lives in melanin-containing tissues”
✓ VerifiedEMA assessment report, p. 29Source ↗

Vonjo

pacritinib · JAK2/FLT3
Immune & cytokine safety
Lymphoid tissue depletion with white blood cell changes consistent with bone marrow suppression in mice, rats and dogs
“Lymphoid tissue depletion and concomitant changes in white blood cell parameters, consistent with bone marrow suppression, were observed in mice, rats, and dogs”
✓ VerifiedFDA integrated review, p. 70Source ↗
Biodistribution & persistence
Mouse: lung exposure 19-fold and brain exposure 2-fold that of plasma
“Pacritinib exposure levels within these three tissues were highest in the lungs (increased 19-fold versus plasma, area under the concentration-time curve [AUC]) followed by the brain (increased 2-fold versus plasma, AUC) and plasma.”
✓ VerifiedFDA integrated review, p. 108Source ↗

Voranigo

vorasidenib · IDH1/IDH2
Immune & cytokine safety
Lymphoid organs (lymph nodes, Peyer's patches, spleen, thymus) among rat target organs
“Additional organs of toxicity in the rat included middle ear, eye, gastrointestinal tract, kidney, lymph nodes, pancreas, Peyer’s patches, pituitary, skin, spleen, and thymus.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Biodistribution & persistence
No significant melanin binding; rat brain-to-plasma ratios 0.604 to 1.24
“There was no significant distribution to melanin-containing tissues. Brain to plasma ratios ranged from 0.604 to 1.24 in rats from the 28-day and 13-week repeat-dose general toxicology studies with ratios decreasing with an increase in dose.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗

Voydeya

danicopan · Complement factor D
Immune & cytokine safety
Alternative-pathway blockade may impair serum bactericidal activity (meningococcal infection risk) when antibody titers are low
“results suggests that when anti-Nm antibody titers are low (i.e., prevaccination), CAP-mediated amplification is required to elicit effective SBA, and hence, there is an increased risk of danicopan promoting bacterial infections under these conditions.”
✓ VerifiedFDA integrated review, p. 72Source ↗
Biodistribution & persistence
Crosses blood-retina barrier; binds melanin in uvea/RPE and skin of pigmented animals
“Distribution studies in either pigmented rats or pigmented rabbits showed that danicopan crosses the blood-retina barrier, enters the neural retina (a tissue that does not contain melanin), and associates with ocular tissues containing melanin (e.g., uvea and choroid-retinal pigment epithelium) and with the skin in pigmented rats.”
✓ VerifiedFDA integrated review, p. 70Source ↗

Vtama

tapinarof · Aryl hydrocarbon receptor
Immune & cytokine safety
Lymphoid depletion with decreased thymus weights in rats at 10 and 40 mg/kg/day subcutaneously
“Additionally, lymphoid depletion was seen in males and females at doses of 10 or 40 mg/kg/day and correlated with thymus weight decreases.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Biodistribution & persistence
Rapid, wide tissue distribution in pigmented rat QWBA, all tissues quantifiable by 1 hour
“In male pigmented rats following a single SC administration of [14C]-tapinarof at 2 mg/kg, radioactivity was rapidly and widely distributed throughout the body with all tissues containing quantifiable radioactivity concentrations by 1-hour post-dose.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗

Vyndaqel

tafamidis · Transthyretin (stabiliser)
Immune & cytokine safety
No specific immunotoxicity studies submitted
“No specific immunotoxicity studies were submitted.”
✓ VerifiedEMA assessment report, p. 22Source ↗
Biodistribution & persistence
Crosses placenta (3-4% of dose to fetal tissues); more than 30% of dose transferred to milk in rats
“Tafamidis was observed to cross the placental barrier and distribute to the foetal tissues to an extent of 3-4% of the administered dose in rats. More than 30% of the dose of tafamidis was transferred to milk when administered to lactating rats.”
✓ VerifiedEMA assessment report, p. 15Source ↗

Wakix

pitolisant · Histamine H3 receptor
Immune & cytokine safety
No changes in haematology, immune organ weights/histology or infections in 6-month rat and 9-month monkey studies; not investigated further
“Chronic administration (6 months in rats, 9 months in monkeys) evidenced no significant change on the following parameters: haematology, immune system organ weights and histology, frequency of infections and tumours including in the two carcinogenicity studies. Therefore, immunotoxicity aspects were not investigated further.”
✓ VerifiedEMA assessment report, p. 24Source ↗
Biodistribution & persistence
Milk concentrations 1–3x plasma in lactating rats
“Radioactivity was measurable in the milk of lactating rats at concentrations 1 to 3 times higher than measured in plasma.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗

Wayrilz

rilzabrutinib · BTK (reversible covalent)
Immune & cytokine safety
No dedicated immunotoxicity studies submitted
“No dedicated immunotoxicity studies were submitted in Module 4.2.3.7.2 of this dossier.”
✓ VerifiedEMA assessment report, p. 43Source ↗
Biodistribution & persistence
Higher concentrations in pigmented tissues (uveal tract, skin) than non-pigmented, suggesting melanin binding
“Rilzabrutinib concentrations in the pigmented tissues (eye uveal, skin) were higher than nonpigmented tissues suggesting rilzabrutinib may interact with melanin.”
✓ VerifiedFDA integrated review, p. 118Source ↗

Welireg

belzutifan · HIF-2α
Immune & cytokine safety
No immunosuppression in repeat-dose toxicity studies
“belzutifan does not show off-target activity, did not induce proliferative changes or potential endocrine/hormonal perturbations, or immunosuppression in repeat-dose toxicity studies”
✓ VerifiedEMA assessment report, p. 46Source ↗
Biodistribution & persistence
Mainly excretory organs and GI tract in rats; no melanin binding
“Distribution studies showed distribution of belzutifan to mostly excretory organs and the GI tract in rats. No gender differences were observed and no melanin binding was evident.”
✓ VerifiedEMA assessment report, p. 45Source ↗

Winlevi

clascoterone · Androgen receptor (topical)
Immune & cytokine safety
Lymphocyte decreases and lymphoid organ atrophy attributed to weak glucocorticoid activity
“The changes observed in the white blood cells population, in the adrenals and in the lymphoid organs (spleen, thymus) were probably related to the weak glucocorticoid activity of the clascoterone.”
✓ VerifiedEMA assessment report, p. 22Source ↗
Biodistribution & persistence
Significant accumulation on repeat dosing (AUC ratio 6.38-20.3 in 9-month dermal minipig study)
“After repeated administrations in some toxicity studies in rats and in minipigs, a significant accumulation was observed (e.g. in 9 months dermal in minipigs, the ratio of AUC ranged from 6.38 to 20.3), varying in extent depending on the doses and treatment duration.”
✓ VerifiedEMA assessment report, p. 20Source ↗

Xcopri

cenobamate · Sodium channel / GABA-A
Immune & cytokine safety
Bone marrow lymphoid hyperplasia in 52-week monkey study, persisting after recovery at high dose
“Lymphoid hyperplasia of bone marrow was seen at the end of the treatment period in the MD and HD groups and was still present after the recovery period at the HD.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Biodistribution & persistence
Rat: wide distribution incl. brain (tissue/blood ratios ~1); highest in kidney (4.7) and liver (2.7)
“Tissue distribution of [14C]-CBM in male S-D rats following a single oral dose showed the highest tissue-to-blood ratios in kidney (4.7) and liver (2.7), with most ratios (including brain) around 1.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗

Xdemvy

lotilaner · Mite GABA-Cl channel
Immune & cytokine safety
Not a skin sensitizer in the mouse local lymph node assay
“In a Local Lymph Node Assay in the mouse, ACH 2224920 did not have the potential to cause skin sensitization.”
✓ VerifiedFDA pharmacology/toxicology review, p. 67Source ↗
Biodistribution & persistence
Accumulates in eyelid margins, with lowest clearance and AUC 10-fold higher than other ocular tissues
“Overall, the data indicated that inferior and superior eyelid margins were prone to drug accumulation, coupled with the lowest clearance in these tissues and an AUC inf 10-fold higher than in all other ocular tissues.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗

Xeglyze

abametapir · Lice metalloproteinases
Immune & cytokine safety
Negative for skin sensitization in mouse LLNA
“A SI of 3.8 was recorded for the positive control group and verifies the validity of the conclusion that abametapir is considered as negative for skin sensitization potential under the conditions used in the assay.”
✓ VerifiedFDA pharmacology/toxicology review, p. 55Source ↗
Biodistribution & persistence
Highest radioactivity at dose site, plasma, kidney, uveal tract/retina and pigmented and non-pigmented skin
“The highest radioactive concentrations and areas under the curve (AUCs) were observed at the dose site, plasma, kidney (cortex and medulla), uveal tract/retina, and skin (both pigmented and non-pigmented).”
✓ VerifiedFDA pharmacology/toxicology review, p. 31Source ↗

Xenleta

lefamulin · Bacterial ribosome (50S PTC)
Immune & cytokine safety
Splenic lymphoid sheath reduction and thymic cortical atrophy in rats after IV dosing
“Following IV administration of lefamulin to rats for 4 or 13 weeks, anemia (all doses), increased coagulation times, and lower organ weights and histopathological changes in spleen (decreased peri-arteriolar lymphoid sheath, decreased size of the marginal zone) and thymus (cortical atrophy) were seen in rats”
✓ VerifiedUS prescribing informationSource ↗
Biodistribution & persistence
Rapid, wide tissue distribution in rat QWBA; skin, soft tissues and lung exceed blood levels
“A quantitative whole-body autoradiography in rats after IV bolus administration showed a rapid distribution into tissues and organs consistent with the apparent low protein binding affinity observed in vitro.”
✓ VerifiedEMA assessment report, p. 31Source ↗

Xocova

ensitrelvir · SARS-CoV-2 3CL protease
Immune & cytokine safety
20-40% decreases in T- and B-cell populations in 4-week monkey study
“Immunophenotyping revealed 20-40% decreases in various T-cell and B-cell populations (males and females).”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Biodistribution & persistence
Highly protein-bound; highest tissue levels in liver; minimal CNS penetration (rat)
“Ensitrelvir was highly protein-bound (97.4% to >98.9%) across all species, predominantly to albumin, with highest tissue concentrations in the liver and minimal CNS penetration (rat distribution study), with excretion occurring primarily through feces and urine.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗

Xolremdi

mavorixafor · CXCR4
Immune & cytokine safety
No immunosuppression in 28-day rat KLH antibody response study
“Twice daily oral administration of mavorixafor for up to 250 mg/kg/day for 28 consecutive days to Sprague-Dawley rats did not result in immunosuppression.”
✓ VerifiedFDA integrated review, p. 158Source ↗
Biodistribution & persistence
Rat QWBA: persistent binding to melanin-containing uveal tract up to 840 h
“In partially pigmented rats, measurable radioactivity was observed in the uveal tract/whole eye from 8 hours until the final sampling time of 840 hours, suggesting irreversible binding to melanin-containing tissues.”
✓ VerifiedFDA integrated review, p. 120Source ↗

Xpovio

selinexor · XPO1
Immune & cytokine safety
Mild grade II dermal contact sensitivity response
“Selinexor was also identified as non-phototoxic and to induce mild-grade II dermal contact sensitivity response at 24 and 48 hours.”
✓ VerifiedEMA assessment report, p. 33Source ↗
Biodistribution & persistence
Highest in kidney, liver and small intestine; no specific binding to pigmented tissues
“The highest concentrations of radioactivity were observed in the kidneys, liver, and small intestine. There was no specific binding to pigmented tissues.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗

Zavzpret

zavegepant · CGRP receptor
Immune & cytokine safety
Non-dose-related lower spleen and thymus weights in monkey without histopathological correlates
“There were increases in the weight of adrenal glands, thyroid/parathyroid, and ovaries and decreases in spleen and thymus in BHV-3500 groups; however, the changes were not dose-related, and there were no histopathological correlates.”
✓ VerifiedFDA pharmacology/toxicology review, p. 32Source ↗
Biodistribution & persistence
Minimal CNS penetration: plasma:olfactory bulb 500:1 and plasma:trigeminal nerve 180:1 after intranasal dosing in rat
“Following intranasal administration of 14C-zavegepant to rats, plasma:olfactory bulb and plasma:trigeminal nerve radioactivity ratios were 500:1 and 180:1, respectively, at 0.5 hours postdose.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗

Zegfrovy

sunvozertinib · EGFR exon 20 insertion
Immune & cytokine safety
Immune organs among the main target organs
“The main target organs were GI tract, eyes, skin, lungs, and immune organs, etc.”
✓ VerifiedFDA multi-discipline review, p. 51Source ↗
Biodistribution & persistence
Melanin binding (uveal tract, meninges, pigmented fur); low blood-brain barrier penetration
“Distribution of sunvozertinib-derived radioactivity in the uveal tract, meninges, and pigmented fur indicated melanin binding. Radioactivity in the brain and spinal cord remained below the limit of quantification, indicating that sunvozertinib has a low tendency to cross the blood-brain barrier.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗

Zenbexus

iberdomide · Cereblon (CELMoD)
Immune & cytokine safety
Immune suppression from lymphoid depletion; decreased neutrophils and lymphocytes, matching clinical neutropenia and infections
“Hematology changes (decreased neutrophils and lymphocytes), immune suppression from lymphoid depletion, and GI toxicity observed in the toxicology studies correlated with neutropenia, infections, and GI toxicity observed in patients in the clinical trials.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Biodistribution & persistence
Prolonged retention in pigmented tissue (reversible melanin association); minimal brain distribution
“This longer presence in the pigmented tissue suggests a reversible association with melanin. There was minimal distribution of radioactivity into the brain of any animal used in the study”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗

Zeposia

ozanimod · S1P1/S1P5 receptor
Immune & cytokine safety
Decreased T and B lymphocytes; suppressed T-dependent IgM and IgG antibody responses
“Immunotoxicity assessment revealed the expected pharmacological action of decreased T- and B-lymphocyte counts and an inhibitory effect on primary and secondary T-dependent IgM and IgG antibody responses.”
✓ VerifiedEMA assessment report, p. 31Source ↗
Biodistribution & persistence
Radioactivity persisted in hippocampus and uveal tract at final time point; BLQ in all other tissues
“At the final time point, radioactivity was still detected in the hippocampus and uveal tract; radioactivity was BLQ in all other tissues.”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗

Zepzelca

lurbinectedin · DNA minor groove (transcription)
Immune & cytokine safety
Lymphocyte and neutrophil decreases suggest a general decrease in immune responsiveness
“dose-dependent decreases in lymphocytes and neutrophils following repeated lurbinectedin administration suggest that there may have been a general decrease in immune responsiveness.”
✓ VerifiedEMA assessment report, p. 38Source ↗
Biodistribution & persistence
Highest tissue levels in spleen, lymph nodes, liver, thyroid, kidney, lung, skin; lowest in brain and testes
“The lowest radioactivity concentrations were detected in the brain (<5 and <2.3 ng-eq/g for male and female rats, respectively) and testes (<12 ng-eq/g). The highest values of total activity were in spleen, followed by lymph nodes, liver, thyroid glands, kidney, lung and skin.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗

Zokinvy

lonafarnib · Farnesyltransferase
Immune & cytokine safety
Lymphoid hypocellularity in spleen, thymus and mesenteric lymph node after 3 months in rats
“In rats, toxicity was seen after 3-months administration of lonafarnib and were attributed as lymphoid hypocellularity and with corresponding weight loss and the affected organs/tissues included spleen, thymus and mesenteric lymph node”
✓ VerifiedEMA assessment report, p. 33Source ↗
Biodistribution & persistence
Low to moderate brain penetration (brain:plasma AUC ~6.5%)
“The AUC ratio of brain to plasma was about 6.5% at each dose level, indicating a low to moderate brain penetration of Lonafarnib.”
✓ VerifiedEMA assessment report, p. 29Source ↗

Ztalmy

ganaxolone · GABA-A receptor (positive modulator)
Immune & cytokine safety
No antigenicity or immunogenicity studies conducted
“No studies for antigenicity, immunogenicity, photosafety have been conducted.”
✓ VerifiedEMA assessment report, p. 35Source ↗
Biodistribution & persistence
Wide distribution in rat QWBA; crosses blood-brain and testis barriers; no melanin binding
“As pigmented and non-pigmented skins were comparably labelled, it is concluded that there is no melanin binding. Radioactivity was found to cross the testis, and blood-brain barrier, and exposure was about 2-fold lower than in blood.”
✓ VerifiedEMA assessment report, p. 29Source ↗

Zulresso

brexanolone · GABA-A receptor (positive modulator)
Immune & cytokine safety
No dermal irritation, skin sensitization or hemolytic potential
“In addition, brexanolone showed no sign of dermal irritation, skin sensitization, or hemolytic potential.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Biodistribution & persistence
CNS tissue radioactivity above blood levels; low levels in testis
“Radioactivity concentrations were observed in CNS tissues at higher than blood concentrations and in testis at low levels.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗

Accrufer

ferric maltol · Iron replacement
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat: absorbed iron bound to transferrin; after IV dosing, highest iron levels in liver and bone marrow, protein-bound
“Radiolabeled iron from ferric maltol in the rat intraduodenal administration studies was found bound to transferrin with a time to half maximal concentration (T½) of 133 minutes. Ferric maltol as single 1000 µg or 1 mg IV doses of iron was administered to rats, resulting in highest iron concentrations in the liver and bone marrow, with the iron being bound to proteins.”
✓ VerifiedFDA multi-discipline review, p. 27Source ↗

Aqneursa

levacetylleucine · Neuronal metabolism (proposed)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
No distribution, milk or placental transfer studies conducted
“No studies of distribution, of excretion in milk and placental transfer with levacetylleucine have been carried out, as levacetylleucine is metabolized by deacetylation (a robust and ubiquitous mechanism), giving rise to a single metabolite, L-leucine, which is endogenously present in humans.”
✓ VerifiedEMA assessment report, p. 25Source ↗

Attruby

acoramidis · Transthyretin (stabiliser)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
No tissue accumulation or retention; no selective association with melanin-containing tissues in pigmented rats
“Overall, there was no accumulation or retention of radioactivity in tissues. The data also suggested that [14C]acoramidis derived radioactivity did not selectively associate with melanin containing tissues in the pigmented rat.”
✓ VerifiedEMA assessment report, p. 27Source ↗

Azstarys

serdexmethylphenidate and dexmethylphenidate · Dopamine/norepinephrine reuptake
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Wide distribution in rat; highest in eye uvea, kidney, liver, gastric mucosa and small intestine
“[14C]SDX-related radioactivity widely distributed in rat tissues with the highest radioactivity concentrations observed in eye uvea, kidney cortex and medulla, liver, gastric mucosa of stomach, and small intestine.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗

Brenzavvy

bexagliflozin · SGLT2
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Highest rat tissue levels in kidney, liver, adrenal, pancreas, harderian and preputial glands
“In a distribution study in rats, the kidney medulla and cortex, liver, adrenal cortex and medulla, pancreas, harderian gland, and preputial gland showed the highest bexagliflozin concentration between 4 to 12 hours postdose.”
✓ VerifiedFDA integrated review, p. 149Source ↗

Caplyta

lumateperone · 5-HT2A / D2 receptor
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Prolonged uveal tract/retina retention (up to 840 h), suggesting melanin binding
“Notably the uveal tract/retina contained 64% and 42% of peak concentrations of radioactivity 336 hr and 840 hr post-dose, respectively, indicating lumateperone-related material may bind to melanin.”
✓ VerifiedFDA multi-discipline review, p. 56Source ↗

Cardamyst

etripamil · L-type calcium channel
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Low exposure in CNS tissues (cerebrum, cerebellum, medulla, spinal cord)
“Central nervous system tissues (cerebrum, cerebellum, medulla, and spinal cord) had low exposure to radioactivity (<100 ng equiv/g).”
✓ VerifiedFDA integrated review, p. 117Source ↗

Cypsedo

cipepofol · GABA-A receptor
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Extensive distribution in rats, highest in adrenal, fat, skin, ovary, pancreas and kidney; crosses blood-brain barrier
“Following IV administration of cipepofol injectable emulsion, extensive tissue distribution was observed in Sprague-Dawley rats, with the highest exposures found in the adrenal gland, fat, skin, ovary, pancreas, and kidney. Cipepofol was demonstrated to cross the blood-brain barrier.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗

Daybue

trofinetide · IGF-1 tripeptide analogue
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Widespread tissue distribution in rat, highest in GI wall, kidney and liver
“Following administration of a single oral dose of 14C-trofinetide (200 mg/kg) to male Sprague Dawley rats, tissue distribution of radioactivity was widespread, with the highest concentrations in gastrointestinal tissue (small and large intestine wall), kidney, and liver;”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗

Filspari

sparsentan · Endothelin A / angiotensin II receptors
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat QWBA: no melanin affinity, none in eye lens; elimination complete in all tissues by 168 h
“No affinity for tissues containing melanin was noted and no quantifiable amount was detected in the eye lens. In all tissues, the elimination of radioactivity was complete by 168 hours postdosing.”
✓ VerifiedFDA integrated review, p. 110Source ↗

Foundayo

orforglipron · GLP-1 receptor (non-peptide)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
No placental transfer in rats: radioactivity absent from fetal blood, tissues and amniotic fluid
“While radioactivity was detected in the amniotic sac and placenta of pregnant rats, it was not detected in fetal blood, fetal tissues, or amniotic fluid, indicating that orforglipron did not cross the placental barrier in rats.”
✓ VerifiedFDA multi-discipline review, p. 56Source ↗

Gemtesa

vibegron · β3-adrenergic receptor
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Associated with eye melanin, not irreversibly bound
“suggesting that vibegron is associated with eye melanin but not irreversibly bound.”
✓ VerifiedEMA assessment report, p. 25Source ↗

Inpefa

sotagliflozin · SGLT1/SGLT2
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
No significant CNS accumulation; no selective association with melanin-containing tissues
“There was no significant accumulation of radioactivity in the central nervous system (CNS), and radioactivity was not selectively associated with the melanin-containing tissues or red blood cells.”
✓ VerifiedEMA assessment report, p. 18Source ↗

Kerendia

finerenone · Mineralocorticoid receptor
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
No specific affinity for melanin-bearing tissues (eye, skin) in pigmented rats
“Similar results were obtained in pigmented Long Evans rats and there was no indication of any specific affinity of substance-associated radioactivity to melanin bearing tissues such as eye wall or skin.”
✓ VerifiedEMA assessment report, p. 30Source ↗

Livmarli

maralixibat · IBAT (ASBT)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Low bioavailability limits tissue distribution; rat liver and pancreas levels ~10x plasma
“Due to maralixibat’s low bioavailability, distribution to other tissues is low, although maralixibat was also found in the liver and pancreas of the rat at levels approximately 10 times higher than plasma.”
✓ VerifiedEMA assessment report, p. 30Source ↗

Lynavoy

linerixibat · IBAT
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Radiolabel studies: drug-related material almost exclusively confined to the GI tract after oral dosing
“Tissue distribution studies using radiolabeled linerixibat revealed that drug-related material was almost exclusively confined to the gastrointestinal tract following oral administration.”
✓ VerifiedFDA integrated review, p. 153Source ↗

Lytgobi

futibatinib · FGFR1-4 (covalent)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat QWBA: radioactivity still high in uveal tract and retinal epithelial cells at 336 h; low in blood, kidney, heart, pigmented skin
“At 336 hrs post dose, radioactivity was still high in the uveal tract and retinal epithelial cells and low but measurable in blood, kidney, heart and skin (pigmented).”
✓ VerifiedEMA assessment report, p. 25Source ↗

Miebo

perfluorohexyloctane · Tear film evaporation barrier
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Topical ocular dosing: highest levels in tears, meibomian glands, cornea, conjunctiva and lacrimal glands
“Following the repeated topical ocular dose of 14C-perfluorohexyloctane, rank order of highest mean concentrations (>5000 ng equivalents 14C-F6H8/g) was: tears > meibomian glands > cornea > palpebral conjunctiva > accessory lacrimal gland > main lacrimal gland > bulbar conjunctiva.”
✓ VerifiedFDA pharmacology/toxicology review, p. 15Source ↗

Modeyso

dordaviprone · DRD2 antagonist / ClpP agonist
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat: distribution to uveal tract, eye, endocrine system, GI tract and meninges; minimal brain exposure
“Dordaviprone distributed to the uveal tract, eye, endocrine system, GI tract, and meninges in rats. Brain exposure was minimal for radiolabeled-dordaviprone in rats.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗

Nereus

tradipitant · NK1 receptor
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Excreted in milk of lactating rats
“Tradipitant was excreted in milk of lactating rats that received tradipitant at 100, 300, or 1000 mg/kg (2.3, 2.4, and 3.3 times the exposure to tradipitant at the MRHD) during pregnancy from gestation day 6 through lactation day 20.”
✓ VerifiedUS prescribing informationSource ↗

Nexletol

bempedoic acid · ATP citrate lyase
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Highest concentrations in liver, kidney and lung; no retention in melanin-containing tissue
“The highest concentrations were found in liver, kidney and lung and contents of the GI tract. The liver is the main target organ of toxicity in rats (see section 4.2). There was no retention in melanin-containing tissue.”
✓ VerifiedEMA assessment report, p. 28Source ↗

Ohtuvayre

ensifentrine · PDE3/PDE4
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
No radioactivity detected in rat brain or spinal cord
“Radioactivity was not detectable in the brain or spinal cord in the rats.”
✓ VerifiedFDA integrated review, p. 80Source ↗

Omlonti

omidenepag isopropyl · EP2 receptor
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Monkey eye: highest in cornea and conjunctiva, lower in iris, ciliary body and choroid-RPE; plasma and blood lowest
“Distribution was: cornea > bulbar conjunctiva > trabecular meshwork > palpebral conjunctiva > sclera > aqueous humor > iris > ciliary body > choroid-retinal pigmented epithelium (RPE) > plasma > blood.”
✓ VerifiedFDA pharmacology/toxicology review, p. 52Source ↗

Orzeyful

oveporexton · Orexin OX2 receptor agonist
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
No melanin binding; placental transfer to fetus and secretion into milk in rats
“liver, with no evidence of binding to melanin-containing tissues. Oveporexton can be transferred into the fetus via the placenta during gestation and is also secreted into milk in lactating rats.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗

Paxlovid

nirmatrelvir and ritonavir · SARS-CoV-2 Mpro (3CL protease)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat QWBA: highest levels in liver, kidney, pancreas and adrenal; no quantifiable brain penetration
“The tissues with the highest Cmax values (Tmax = 4 hours for most tissues) excluding the gastrointestinal tract were observed in the liver, kidney, pancreas, and adrenal gland. [14C]nirmatrelvir-derived radioactivity did not cross the blood:brain barrier to a quantifiable extent.”
✓ VerifiedFDA integrated review, p. 190Source ↗

Pizensy

lactitol · Osmotic laxative
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
No dedicated distribution study; in rats lactitol reached mg/g levels throughout the intestine including colon
“Distribution study was not performed. However, GI distribution of lactitol was examined in a pharmacology study in rats after an oral dose of 4 g/kg. Lactitol reached in mg/g levels in all intestinal components including the colon.”
✓ VerifiedFDA multi-discipline review, p. 32Source ↗

Pyrukynd

mitapivat · Pyruvate kinase (activator)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Distribution to pigmented skin and uveal tract; potential melanin binding
“The distribution of [14C]mitapivat to melanin-containing tissues, such as pigmented skin and the uveal tract of the ocular system, indicates that mitapivat has the potential to bind melanin.”
✓ VerifiedFDA integrated review, p. 141Source ↗

Quviviq

daridorexant · Orexin OX1/OX2 receptors
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat QWBA: no accumulation in uveal tract, pigmented skin or meninges; no melanin binding
“There was no significant distribution/accumulation of radioactivity in the uveal tract/retina, pigmented skin, or meninges of the brain, suggesting that daridorexant does not bind to melanin.”
✓ VerifiedFDA integrated review, p. 170Source ↗

Recarbrio

imipenem, cilastatin and relebactam · Beta-lactamase (relebactam)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Low brain, lens and bone levels in rat QWBA; relebactam not prone to cross the blood-brain barrier
“Brain, seminal vesicles, eye lens and bone were among the tissues with lowest concentrations of radioactivity (<1.5 μg equiv/g at Tmax). The low levels of radioactivity in the brain suggests REL is not prone to pass the blood brain barrier.”
✓ VerifiedEMA assessment report, p. 27Source ↗

Relyvrio

sodium phenylbutyrate and taurursodiol · ER stress / mitochondrial (proposed)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat: phenylbutyrate highest in kidney with minimal CNS levels; taurursodiol below quantification in CNS
“Based on radioactivity, PB-related material accumulated in kidney while CNS levels were minimal (i.e., 10-fold lower than kidney); radiolabeled TUDCA-related material was below the limits of quantification in CNS tissue.”
✓ VerifiedFDA pharmacology/toxicology review, p. 46Source ↗

Simtriyo

centanafadine · Triple monoamine reuptake
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Not stated in public reviews

Truseltiq

infigratinib · FGFR1-3
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Extensive tissue distribution including brain; specific uptake into melanin-containing structures in pigmented rats
“[14C]‐infigratinib was extensively distributed into peripheral tissues in rats after oral and IV doses, including brain, and was specifically taken up into melanin‐containing structures in pigmented rats.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗

Tryvio

aprocitentan · Endothelin A/B receptors
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Highest in liver, kidney cortex, lung, pituitary, thyroid, myocardium; no retention in uvea, pigmented skin or brain meninges
“The liver, kidney cortex, lung, pituitary, thyroid, and myocardium showed the highest exposures, with peak exposures observed at 8 hours postdose. No relevant retention of radioactivity in the uveal tract/retina, pigmented skin, or meninges of the brain was observed at any time point.”
✓ VerifiedFDA integrated review, p. 122Source ↗

Ubrelvy

ubrogepant · CGRP receptor
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Widely distributed to most tissues and rat milk at concentrations similar to blood
“Following oral administration to rats and monkeys, [14C]ubrogepant was approximately 23% bioavailable and was widely distributed to most tissues and milk (rat) at similar concentrations to blood.”
✓ VerifiedFDA pharmacology/toxicology review, p. 18Source ↗

Veppanu

vepdegestrant · Estrogen receptor (PROTAC degrader)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Highest in liver, ovaries, kidneys, thyroid, spleen; melanin binding (uveal tract, eye, pigmented skin)
“Following oral administration of [14C]- vepdegestrant and whole-body autoradiography, the highest distribution of vepdegestrant in rats was in the liver, ovaries, kidneys, thyroid, spleen, and melanin-containing tissues (uveal tract, whole eye, and pigmented skin).”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗

Vivjoa

oteseconazole · Fungal CYP51
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Highest levels in small intestine and Harderian gland (rat); half-life 30 days in dogs, 8.5 days in rats
“The half-life was 30 days in dogs and 8.5 days in rats. In a tissue distribution study in rats, the highest levels of oteseconazole were observed in the small intestines and in the Harderian gland.”
✓ VerifiedFDA integrated review, p. 72Source ↗

Vizz

aceclidine · Muscarinic agonist (miotic)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rabbit eye: metabolite distributed to all ocular tissues within 30 min; highest in cornea and iris
“3-quinuclidinol distributed to all ocular tissues analyzed within 30 minutes of treatment. The rank order of the exposure was: cornea > iris > choroid > aqueous humor > sclera > retina > lens ≈ vitreous humor.”
✓ VerifiedFDA integrated review, p. 78Source ↗

Voquezna

vonoprazan · H+/K+-ATPase (potassium-competitive)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Wide distribution in rats, highest in liver, kidney, intestine, lung and stomach wall; low in brain and spinal cord
“In rats, vonoprazan and its metabolites were widely distributed with higher concentration in the liver, kidney, intestine, lung, and stomach wall than in the plasma, and were low in the brain and the spinal cord.”
✓ VerifiedFDA integrated review, p. 137Source ↗

Xacduro

sulbactam and durlobactam · PBPs; beta-lactamase (durlobactam)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat: low brain and spinal cord levels (tissue/blood <0.1); no blood-brain barrier penetration
“Concentrations in the brain and spinal cord were low throughout with tissue/blood ratios of <0.1, indicating that test material-related radioactivity had not penetrated the blood-brain barrier.”
✓ VerifiedFDA integrated review, p. 94Source ↗

Zaynich

cefepime and zidebactam · PBPs; beta-lactam enhancer (zidebactam)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat: highest concentrations in kidney, plasma and urinary bladder wall
“Distribution: 100 mg/kg [14C]-WCK 5107, administered intravenously, distributed in the highest concentrations (> 200 to 4420 mcg equivalents/g tissue) to kidney (medulla and inner and outer cortex), plasma, and urinary bladder wall.”
✓ VerifiedFDA integrated review, p. 244Source ↗

Zevtera

ceftobiprole medocaril · Penicillin-binding proteins
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Rat QWBA: radioactivity in all tissues with low overall distribution
“In a rat exploratory quantitative whole body autoradiography study following a single intravenous administration of 14C radiolabeled ceftobiprole medocaril sodium (20 mg/kg), quantifiable levels of radioactivity (>0.29 mcg-equiv/g) were detected in all tissues with a low overall distribution into most organs and tissues.”
✓ VerifiedFDA integrated review, p. 246Source ↗

Zurzuvae

zuranolone · GABA-A receptor (positive modulator)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
High brain penetration; brain:plasma ratio 2.23 (mouse) and 3.22 (rat)
“The brain to plasma ratio of zuranolone was 2.23 after IP injection (1 mg/kg) (SSN-868) in male mice and 3.22 (Study No. SSN-01237) after oral administration in male rats.”
✓ VerifiedFDA integrated review, p. 155Source ↗

Zycubo

copper histidinate · Copper replacement (Menkes disease)
Immune & cytokine safety
Not stated in public reviews
Biodistribution & persistence
Not stated in public reviews